Compounds for the treatment of neuromuscular disorders

Abstract

The present disclosure relates to compounds suitable for treating, ameliorating and / or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC-1 ion channel.

Description

[0001]P7162PC00 1 Compounds for the treatment of neuromuscular disorders Technical fieldThe present disclosure relates to compounds and their use in treating, amelioratingand / or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC-1 ionchannel. The disclosure further relates to methods of treating, preventing and / orameliorating neuromuscular disorders, by administering said composition to a person in need thereof. Background Walking, breathing, and eye movement are examples of essential everyday physiological activities that are powered by the contractile activity of skeletal muscle. Skeletal muscles are inherently in a resting state and contractile activity occurs exclusively in response to commands from the central nervous system (CNS). Such neuronal commands take the form of action potentials that travel from the brain to the muscle fibres in several steps. The neuromuscular junction (NMJ) is a highly specialized membrane area on muscle fibres where motor neurons come into close contact with the muscle fibres, and it is at the NMJ where neuronal action potentials aretransmitted to muscular action potentials in a one-to-one fashion via synaptictransmission.Unfortunately, none of the currently employed drug regimens for treatingneuromuscular disorders, such as myasthenia gravis, Lambert-Eaton Syndrome, Charcot-Marie Tooth (CMT) disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) and sarcopenia, have been able to fully restore muscle function in compromised patients. The ClC-1 ion channel (Pedersen, T.H., Riisager, A., Vincenzo de Paoli, F., Chen, T-Y, Nielsen, O.B. Role of physiological ClC-1 Cl- ion channel regulation for the excitabilityand function of working skeletal muscle. J. Gen. Physiol.2016, 147, 291 – 308) isemerging as a target for improving muscle function in patients having a neuromuscular disfunction. P7162PC00 2 SummaryThe present disclosure comprises a series of compounds that can alleviate disorders ofthe neuromuscular junction through inhibition of ClC-1 channels. It has been found that compounds that inhibit ClC-1 ion channels are capable of restoring neuromuscular transmission, as evidenced by the data generated by investigation of the compound set in biological models described herein. These compounds thus constitute a group of potential drugs that can be used to treat and / orameliorate muscle weakness and / or muscle fatigue in neuromuscular junctiondisorders caused by disease or by neuromuscular blocking agents.The present disclosure is directed to ClC-1 ion channel inhibitors with application in thetreatment of a range of conditions, such as reversal of neuromuscular block, SMA, CMT, ALS and myasthenic conditions, in which muscle activation by the nervous system is compromised and symptoms of weakness and fatigue are prominent.In one aspect, the present invention relates to a compound of Formula (I): Formula (I) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;wherein R5 and R6, or R5 and R9, or R5 and R10, or R5 and R12, or R6 and R9, orR6 and R10, or R6 and R12, or R7 and R8, or R9 and R10, or R9 and R11, orR10 and R11, or R11 and R12, are optionally joined together to form a ringtogether with the intervening atom(s); -R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C2-3 P7162PC00 3 alkenyl optionally substituted with one or more, identical or different, substituents R13; -OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -OC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; - SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14and -SC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; and- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14; or R1is linked to R2to form a ring together with the intervening atoms, and R1 is C1-3 alkanediyl optionally substituted with one or more, identical ordifferent, substituents R13, or -O-C1-3 alkanediyl optionally substitutedwith one or more, identical or different, substituents R13, and R2is C1-3 alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:, - R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,or when R5 is linked to R6, R9, R10 or R12 to form a ring, then R5 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13; P7162PC00 4- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R6 is linked to R5, R9, R10 or R12 to form a ring, then R6 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, or when R7 is linked to R8 to form a ring, then R7 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, or when R8 is linked to R7 to form a ring, then R8 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R9 is linked to R5, R6, R10 or R11 to form a ring, then R9 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R10is linked to R5, R6, R9or R11, then R10is C1-3 alkanediyl optionally substituted with one or more, identical or different, substituents R13;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,or when R11 is linked to R9, R10, or R12, then R11 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13; P7162PC00 5- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R12 is linked to R5, R6, or R11, then R12 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium, F, Cl,and CN;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8 bicycloalkyl;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F;- R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl;- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, P7162PC00 6 CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof; with the proviso that the compound is not selected from the group consisting of 5-(6-fluoro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4-oxazolidinedione and 5-(6-chloro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4- oxazolidinedione.In another aspect, the disclosure concerns a compound as defined herein for use intreating, ameliorating and / or preventing a neuromuscular disorder, and / or for use in reversing and / or ameliorating a neuromuscular blockade. In yet another aspect, thedisclosure concerns a composition comprising a compound as defined herein.Definitions The terms “C1-3 alkyl” and "C1-5 alkyl" refers to a branched or unbranched alkyl group having from one to three or one to five carbon atoms respectively, including but not limited to methyl, ethyl, prop-1-yl, prop-2-yl, 2-methyl-prop-1-yl, 2-methyl-prop-2-yl, 2,2- dimethyl-prop-1-yl, but-1-yl, but-2-yl, 3-methyl-but-1-yl, 3-methyl-but-2-yl, pent-1-yl, pent-2-yl and pent-3-yl. The term "alkanediyl" refers to the corresponding derivative of an alkyl group having two bonding sites. Thus, a C1-3 alkanediyl refers to –(CH2)n-, wherein n is a positive integer from 1 to 3, i.e. including -CH2-, -CH2CH2-, and -CH2CH2CH2-. The term "C2-3 alkenyl" and "C2-5 alkenyl" refers to a branched or unbranched alkenyl group having from two to three or two to five carbon atoms respectively, two of which are connected by a double bond, including but not limited to ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl and isopentenyl. The term "C2-5 alkynyl" refers to a branched or unbranched alkynyl group having from two to five carbon atoms, two of which are connected by a triple bond, including but not limited to ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, buta-1,3- P7162PC00 7 diynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, penta-2,4-diynyl and penta- 1,3-diynyl. The term "C3-5cycloalkyl" and "C3-6cycloalkyl" refers to a group having three to five or three to six carbon atoms respectively including a monocyclic or bicyclic carbocycle, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term “C5-8bicycloalkyl” as used herein refers a bicyclic ring system, wherein both cycloalkyl rings share the same two ring atoms. The term “C5-8bicycloalkyl” includes bridged bicyclic compounds, i.e. wherein the two rings share three or more atoms, separating the two bridgehead atoms by a bridge containing at least one atom. For example, the term “C5-8bicycloalkyl” includes bicyclo[1.1.1]pentyl. For example, the term “C5-8bicycloalkyl” .The term “heterocycle” as used herein refers to a monocyclic or bicyclic, heterocyclicring which is either saturated, unsaturated, or aromatic, and which contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur. The term “C5heterocycle” as used herein refers to a 5-membered heterocycle.The term "5- to 10-membered heteroaryl" refers to a monovalent, aromatic heterocyclicgroup having one or more heteroatoms, preferably one to three heteroatoms, selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom. Theterm "5- to 10-membered heteroaryl" encompasses an aromatic heterocyclic groupcondensed with an aromatic or non-aromatic carbocyclic ring or an aromatic or non- aromatic heterocyclic ring to form a bicyclic group, and also encompasses an aromatic carbocyclic group condensed with an aromatic or non-aromatic heterocyclic ring to form a bicyclic group. Binding to the heteroaryl may be via a heteroatom or via a carbon atom of the heteroaryl.In some embodiments, the 5- to 10-membered heteroaryl is a 5-membered heteroaryl.The term "5-membered heteroaryl" refers to a monovalent, aromatic ring system having 5 ring atoms and which contains at least one heteroatom which may be identical or different, said heteroatom being oxygen, nitrogen or sulfur.5-membered heteroaryls P7162PC00 8 include but are not limited to oxazolyl, thiazolyl, thiadiazolyl, oxadiazolyl, triazolyl, pyrrolyl, thienyl, furanyl, diazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, and tetrazolyl. In one embodiment, the 5-membered heteroaryl is furanyl, such as furan-2- yl. In one embodiment, the 5-membered heteroaryl is thienyl, such as thien-2-yl orthien-3-yl. In one embodiment, the 5-membered heteroaryl is thiazolyl, such as thiazol-2-yl. In one embodiment, the 5-membered heteroaryl is oxazolyl, such as oxazol-2-yl.In some embodiments, the 5- to 10-membered heteroaryl is a 6-membered heteroaryl.The term "6-membered heteroaryl" refers to a monovalent, aromatic ring system having 6 ring atoms and which contains at least one heteroatom which may be identical or different, said heteroatom being oxygen, nitrogen or sulfur.6-membered heteroaryls include but are not limited to pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl.In some embodiments, the 5- to 10-membered heteroaryl is a 8-membered heteroaryl.The term "8-membered heteroaryl" refers to a monovalent, aromatic ring system having 8 ring atoms and which contains at least one heteroatom which may be identical or different, said heteroatom being oxygen, nitrogen or sulfur.8-membered heteroaryls include but are not limited to groups encompassing an aromatic heterocyclic group condensed with an aromatic or non-aromatic carbocyclic ring or an aromatic or non- aromatic heterocyclic ring to form a bicyclic group, and also groups encompassing an aromatic carbocyclic group condensed with an aromatic or non-aromatic heterocyclic ring to form a bicyclic group.8-membered heteroaryls include but are not limited to 1,4- dihydropyrrolo[3,2-b]pyrrolyl, 1,6-dihydropyrrolo[2,3-b]pyrrolyl, 6H-furo[2,3-b]pyrrole, 4H-furo[2,3-b]pyrrolyl, 6H-thieno[2,3-b]pyrrolyl and 4H-thieno[2,3-b]pyrrolyl.In some embodiments, the 5- to 10-membered heteroaryl is a 9-membered heteroaryl.The term "9-membered heteroaryl" refers to a monovalent, aromatic ring system having 9 ring atoms and which contains at least one heteroatom which may be identical or different, said heteroatom being oxygen, nitrogen or sulfur.9-membered heteroaryls include but are not limited to groups encompassing an aromatic heterocyclic group condensed with an aromatic or non-aromatic carbocyclic ring or an aromatic or non- aromatic heterocyclic ring to form a bicyclic group, and also groups encompassing an aromatic carbocyclic group condensed with an aromatic or non-aromatic heterocyclic ring to form a bicyclic group.9-membered heteroaryls include but are not limited to indolyl, isoindolyl, indolizinyl, indazolyl, benzimidazolyl, azaindolyl, azaindazolyl, P7162PC00 9 pyrazolo[1,5-a]pyrimidinyl, purinyl, benzofuranyl, benzo[b]thiophenyl, benzisoxazolyl, benzthiazolyl, benzisothiazolyl, and benzo[c][1,2,5]thiadiazolyl.In some embodiments, the 5- to 10-membered heteroaryl is a 10-membered heteroaryl.The term "10-membered heteroaryl" refers to a monovalent, aromatic ring system having 10 ring atoms and which contains at least one heteroatom which may be identical or different, said heteroatom being oxygen, nitrogen or sulfur.10-membered heteroaryls include but are not limited to groups encompassing an aromaticheterocyclic group condensed with an aromatic or non-aromatic carbocyclic ring or anaromatic or non-aromatic heterocyclic ring to form a bicyclic group, and also groups encompassing an aromatic carbocyclic group condensed with an aromatic or non- aromatic heterocyclic ring to form a bicyclic group.10-membered heteroaryls include but are not limited to quinolinyl, isoquinolinyl, 4H-quinolizinyl, quinoxalinyl, phthalazinyl, quinazolinyl, cinnolinyl, 1,8-naphthyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[4,3- d]pyrimidinyl, pyrido[3,4-b]pyrazinyl, pyrido[2,3-b]pyrazinyl and pteridinyl. The term "aryl" as used herein represents a mono-, bicyclic, or multicyclic carbocyclic ring system having one or two aromatic rings. The term "C6-10 aryl" refers to an aryl group having 6 to 10 carbon atoms, for example a phenyl group or a naphthyl group. As described herein, compounds of the present invention may contain “substituted” moieties. In general, the term “substituted” means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at one or more substitutable position of the group, and when more than one position in any given structure is substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position, i.e. the substituent may be individually / independently selected from a group of substituents. Combinations of substituents envisioned by the present invention are preferably those that result in the formation of stable or chemically feasible compounds. The term “spiro compound” as used herein refers to a compound having one atom (usually a quaternary carbon) as the only common member of two rings. P7162PC00 10 Compounds of the invention also include tautomeric forms. The term “tautomer” asused herein refers to one of two or more isomers of a compound that exist together inequilibrium, and are readily interchanged by migration of an atom, e.g., a hydrogenatom, or group within the molecule. Tautomerism is of the general form: Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge, i.e. “G” in the formula above is H+. Example prototropictautomers include ketone – enol pairs, amide - imidic acid pairs, lactam – lactim pairs,enamine – imine pairs, and annular forms where a proton can occupy two or morepositions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and4H- 1,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. Tautomeric formscan be in equilibrium or sterically locked into one form by appropriate substitution. Tautomeric forms can also include methyltropic tautomers, which result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a methyl group. The term “half-life” as used herein is the time it takes for the compound to lose one-half of its pharmacologic activity. The term "plasma half-life" is the time that it takes the compound to lose one-half of its pharmacologic activity in the blood plasma. The term “treatment” refers to the combating of a disease or disorder. “Treatment” or “treating,” as used herein, includes any desirable effect on the symptoms or pathology of a disease or condition as described herein, and may include even minimal changes or improvements in one or more measurable markers of the disease or condition being treated. “Treatment” or “treating” does not necessarily indicate complete eradication or cure of the disease or condition, or associated symptoms thereof. In some embodiments, the term “treatment” encompasses amelioration and prevention. The term “amelioration” refers to moderation in the severity of the symptoms of a disease or condition. Improvement in a patient's condition, or the activity of making an effort to correct, or at least make more acceptable, conditions that are difficult to endure related to patient's conditions is considered “ameliorative” treatment. P7162PC00 11 The term “prevent” or “preventing” refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance action. The term “reversal” or “reversing” refers to the ability of a compound to restore nerve-stimulated force in skeletal muscle exposed either ex vivo or in vivo to a non-depolarizing neuromuscular blocking agent or another pharmaceutical that is able to depress neuromuscular transmission The term “non-depolarizing blockers” refers to pharmaceutical agents that antagonize the activation of acetylcholine receptors at the post-synaptic muscle fibre membrane by blocking the acetylcholine binding site on the receptor. These agents are used to block neuromuscular transmission and induce muscle paralysis in connection with surgery. The term “ester hydrolysing reagent” refers to a chemical reagent which is capable of converting an ester functional group to a carboxylic acid with elimination of the alcohol moiety of the original ester, including but not limited to acid, base, a fluoride source, PBr3, PCl3 and lipase enzymes. The term “total membrane conductance (Gm)” is the electrophysiological measure of the ability of ions to cross the muscle fibre surface membrane. It reflects the function of ion channels that are active in resting muscle fibres of which ClC-1 is known to contribute around 80 % in most animal species. Detailed description CompoundsIt is within the scope of the present disclosure to provide a compound for use intreating, ameliorating and / or preventing neuromuscular disorders that reduce neuromuscular function. As disclosed herein, inhibition of ClC-1 improves or restoresneuromuscular function. The compounds of the present disclosure comprisecompounds capable of inhibiting the ClC-1 channel thereby improving or restoring neuromuscular function.In one aspect, the present invention relates to a compound of Formula (I): P7162PC00 12 Formula (I) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;wherein R5 and R6, or R5 and R9, or R5 and R10, or R5 and R12, or R6 and R9, orR6 and R10, or R6 and R12, or R7 and R8, or R9 and R10, or R9 and R11, orR10 and R11, or R11 and R12, are optionally joined together to form a ringtogether with the intervening atom(s); -R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C2-3alkenyl optionally substituted with one or more, identical or different, substituents R13; -OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -OC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; - SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14and -SC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; and- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14; or R1is linked to R2to form a ring together with the intervening atoms, and R1 is C1-3 alkanediyl optionally substituted with one or more, identical ordifferent, substituents R13, or -O-C1-3 alkanediyl optionally substitutedwith one or more, identical or different, substituents R13, and R2is C1-3 alkanediyl optionally substituted with one or more, identical or different,substituents R13; P7162PC00 13- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:, - R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,or when R5 is linked to R6, R9, R10 or R12 to form a ring, then R5 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R6 is linked to R5, R9, R10 or R12 to form a ring, then R6 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, or when R7 is linked to R8 to form a ring, then R7 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, or when R8 is linked to R7 to form a ring, then R8 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13; P7162PC00 14- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R9 is linked to R5, R6, R10 or R11 to form a ring, then R9 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R10is linked to R5, R6, R9or R11, then R10is C1-3alkanediyl optionally substituted with one or more, identical or different, substituents R13;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,or when R11 is linked to R9, R10, or R12, then R11 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R12 is linked to R5, R6, or R11, then R12 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium, F, Cl,and CN;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17; P7162PC00 15 -R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8bicycloalkyl; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; -R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof; with the proviso that the compound is not selected from the group consisting of 5-(6-fluoro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4-oxazolidinedione and 5-(6-chloro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4- oxazolidinedione.In one aspect, the present invention relates to a compound of Formula (I): P7162PC00 16 Formula (I) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;wherein R5 and R6, or R5 and R9, or R5 and R10, or R5 and R12, or R6 and R9, orR6 and R10, or R6 and R12, or R7 and R8, or R9 and R10, or R9 and R11, orR10 and R11, or R11 and R12, are optionally joined together to form a ringtogether with the intervening atom(s); -R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C2-3alkenyl optionally substituted with one or more, identical or different, substituents R13; -OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -OC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; - SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14and -SC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; and- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14; or R1is linked to R2to form a ring together with the intervening atoms, and R1 is C1-3 alkanediyl optionally substituted with one or more, identical ordifferent, substituents R13, or -O-C1-3 alkanediyl optionally substitutedwith one or more, identical or different, substituents R13, and R2is C1-3 alkanediyl optionally substituted with one or more, identical or different,substituents R13; P7162PC00 17- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:, - R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,or when R5 is linked to R6, R9, R10 or R12 to form a ring, then R5 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R6 is linked to R5, R9, R10 or R12 to form a ring, then R6 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, or when R7 is linked to R8 to form a ring, then R7 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, or when R8 is linked to R7 to form a ring, then R8 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13; P7162PC00 18- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R9 is linked to R5, R6, R10 or R11 to form a ring, then R9 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R10is linked to R5, R6, R9or R11, then R10is C1-3alkanediyl optionally substituted with one or more, identical or different, substituents R13;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,or when R11 is linked to R9, R10, or R12, then R11 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R12 is linked to R5, R6, or R11, then R12 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium, F, Cl,and CN;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17; P7162PC00 19 -R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, identical or different, substituents R17, 5- to10-membered heterocycle optionally substituted with one or more,identical or different, substituents R19, 5- to 10-membered heteroaryloptionally substituted with one or more, identical or different, substituents R17, and C5-8bicycloalkyl; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl, and C3-5 cycloalkyl;- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof; with the proviso that the compound is not selected from the group consisting of 5-(6-fluoro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4-oxazolidinedione and 5-(6-chloro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4- oxazolidinedione. In some embodiments, the compound of the present invention is not 5-(6-fluoro-3,4- dihydro-2H-1-benzopyran-8-yl)-2,4-oxazolidinedione, also known as 5-(6- fluorochroman-8-yl)oxazolidine-2,4-dione. In some embodiments, the compound of the present invention is not 5-(6-chloro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4- oxazolidinedione, also known as 5-(6-chlorochroman-8-yl)oxazolidine-2,4-dione. In some embodiments, the compound is of formula (VIII): P7162PC00 20 Formula (VIII) wherein M, Q, T, X, Z, R1to R3and R5to R19are as defined herein. In some embodiments, the compound is of formula (IX): Formula (IX) wherein M, Q, T, X, Z, R1to R3and R5to R20are as defined herein. In some embodiments, the compound is of formula (X): Formula (X) wherein M, Q, T, X, Z, R1to R3and R5to R20are as defined herein. In some embodiments, the compound is of formula (XI): P7162PC00 21 Formula (XI) wherein M, Q, T, X, Z, R1to R3and R5to R19are as defined herein. In some embodiments, the compound is of formula (XII) wherein M, Q, T, X, Z, R1to R3and R5to R19are as defined herein. Formula (XII) In some embodiments, X is absent and T is directly linked to Z. Thus, in someembodiments, the compound is of formula (II): Formula (II) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - OC1-3alkyl optionally substituted with one or more, identical or different, P7162PC00 22 substituents R14; and -SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14;- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14;- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:, - R5 selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, P7162PC00 23 substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8 bicycloalkyl;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F;- R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; P7162PC00 24 -R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is of formula (III) or formula (IV), wherein M, Q, T, Z, R1to R3and R5to R20are as defined herein. Formula (III) Formula (IV)In some embodiments, the compound is of formula (III): Formula (III) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S; P7162PC00 25- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; and -SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14;- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14;- R3 is selected from the group consisting of H; F and Cl;- R5 selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15; P7162PC00 26- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, and 5- to 10-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F;- R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; and- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O;or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. P7162PC00 27In some embodiments, the compound is of formula (IV): Formula (IV) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - OC1-3 alkyl optionally substituted with one or more, identical or different, substituents R14; and -SC1-3 alkyl optionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3 cycloalkyl optionally substituted with one or more, identical or different, substituents R14; -R3 is selected from the group consisting of H; F and Cl;- R5 selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; -R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13; P7162PC00 28- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, and 5- to 10-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17; P7162PC00 29 -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; -R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.In some embodiments, the compound is of formula (V): Formula (V) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - OC1-3 alkyl optionally substituted with one or more, identical or different, substituents R14; and -SC1-3 alkyl optionally substituted with one or more, identical or different, substituents R14; P7162PC00 30- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14;- R3 is selected from the group consisting of H; F and Cl;- R5 selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl; P7162PC00 31 -R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17; -R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, and 5- to 10-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; -R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.In some embodiments, the compound is of formula (VI): P7162PC00 32 Formula (VI) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - OC1-3 alkyl optionally substituted with one or more, identical or different, substituents R14; and -SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14; -R3 is selected from the group consisting of H; F and Cl;- R5 selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; -R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13; -R8 is independently selected from the group consisting of H, deuterium, F,and C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13; P7162PC00 33- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19 and 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, P7162PC00 34 CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; and- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O;or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.In some embodiments, the compound is of formula (VII): Formula (VII) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; and -SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3 cycloalkyl optionally substituted with one or more, identical or different, substituents R14; -R3 is selected from the group consisting of H; F and Cl; P7162PC00 35- R5 selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical P7162PC00 36 or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17; -R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19 and 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; and- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; andor a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.In some embodiments, the compound is of formula (II): Formula (II) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8; P7162PC00 37- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; and-OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14;- R2 is selected from the group consisting of F; Cl; Br; and C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14;- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:, - R5 selected from the group consisting of H; deuterium; F; and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, P7162PC00 38 substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is H or C1-3 alkyl optionally substituted with one or more, identical ordifferent, substituents R13;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, andCl;- R14 is independently selected from the group consisting of deuterium, F, Cl,and CN;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8 bicycloalkyl;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F;- R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl;- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O, and- R20 is independently selected from the group consisting of H, deuterium andF; P7162PC00 39 or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.In some embodiments, the compound is of formula (II): Formula (II) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; and -OC1-3 alkyloptionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; and Br;- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:, -R5 selected from the group consisting of H; deuterium; F; and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; -R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; P7162PC00 40- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is H or C1-3 alkyl optionally substituted with one or more, identical ordifferent, substituents R13;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, andCl;- R14 is independently selected from the group consisting of deuterium, F, Cl,and CN;- R16 is independently selected from the group consisting of C1-3 alkyloptionally substituted with one or more F, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-membered heterocycle optionally substitutedwith one or more, identical or different, substituents R19 and 5- to 10-membered heteroaryl optionally substituted with one or more, identicalor different, substituents R17;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, cyano, Cl, Br, and F; P7162PC00 41 -R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, cyano, Cl, Br, and F; and -R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.In one aspect, the present invention relates to a compound of Formula (I): Formula (I) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C2-3alkenyl optionally substituted with one or more, identical or different, substituents R13; -OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -OC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; - SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14and -SC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; and- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3 cycloalkyl optionally substituted with one or more, identical or different, substituents R14; -R3 is selected from the group consisting of H; F and Cl; P7162PC00 42- R4 is selected from the group consisting of:, - R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13,- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13,- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13,- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13,- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyl P7162PC00 43 optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium, F, Cl,and CN;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8 bicycloalkyl;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F;- R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl;- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano,Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; P7162PC00 44 or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof; with the proviso that the compound is not selected from the group consisting of 5-(6-fluoro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4-oxazolidinedione and 5-(6-chloro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4- oxazolidinedione.In one aspect, the present invention relates to a compound of Formula (I): Formula (I) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C2-3alkenyl optionally substituted with one or more, identical or different, substituents R13; -OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -OC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; - SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14and -SC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; and- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3 cycloalkyl optionally substituted with one or more, identical or different, substituents R14; -R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of: P7162PC00 45 ;- R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13,- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13,- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13,- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13,- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl; P7162PC00 46- R14 is independently selected from the group consisting of deuterium, F, Cl,and CN;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8 bicycloalkyl;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F;- R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl;- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof; with the proviso that the compound is not selected from the group consisting of 5-(6-fluoro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4-oxazolidinedione P7162PC00 47 and 5-(6-chloro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4- oxazolidinedione.In some embodiments, the compound is of Formula (I): Formula (I) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; and -OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14; -R3 is H or F;- R4 is selected from the group consisting of: P7162PC00 48 , -R5 is selected from the group consisting of H; deuterium; F; and C1-3 alkyl;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyl;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3 alkyl; -R8 is independently selected from the group consisting of H, deuterium, F,and C1-3 alkyl; -R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyl;- R10 is selected from the group consisting of H; deuterium; F; and C1-3 alkyl;- R11 is H or C1-3 alkyl optionally substituted with one or more, identical ordifferent, substituents R13; -R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R16 is independently selected from the group consisting of -OR18, -OCH2R18,C1-3 alkyl optionally substituted with one or more F, -C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17, and 5- to 6-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, Cl, Br, and F; P7162PC00 49 -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is of formula (III) or formula (IV): Formula (III) Formula (IV) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; and -OC1-3 alkyloptionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; Br; and C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14; -R3 is H;- R5 is selected from the group consisting of H; deuterium and F;- R6 is selected from the group consisting of H, deuterium and F;- R7 is independently selected from the group consisting of H, deuterium, andMe; P7162PC00 50 -R8 is independently selected from the group consisting of H, deuterium andMe; -R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; -R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H and Me;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R16 is independently selected from the group consisting of -OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or more F, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6 aryl optionally substituted with one or more, identical or different, substituents R17 and 5-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. P7162PC00 51 In some embodiments, M is CR5R6. In some embodiments, R5and R6are H. In some embodiments, M is CH2. In some embodiments, M is NR11. In some embodiments, R11is C1-3alkyl, such as CH3. In some embodiments, M is N(CH3). In some embodiments, M is O. In some embodiments, M is S. Q is Q is CR7R8. In some embodiments, R7and R8are H. Thus, in some embodiments, Q is CH2. In some embodiments, R7and R8are CH3. Thus, in some embodiments, Q is C(CH3)2. T is CR7R8. In some embodiments, R7and R8are H. Thus, in some embodiments, T isCH2. In some embodiments, T is C(CH3)2.In some embodiments, X is absent. When X is absent, T is directly linked to Z. In some embodiments, X is CR7R8. In some embodiments, R7and R8are H. Thus, in some embodiments, X is CH2. In some embodiments, Z is CR10R9. In some embodiments, R9and R10are H. Thus, in some embodiments, Z is CH2. In some embodiments, R9and R10are F. Thus, in some embodiments, Z is CF2. In some embodiments, Z is NR12. In some embodiments, R12is H. Thus, in some embodiments, Z is N(H). In some embodiments, R12is CH3. Thus, in some embodiments, Z is N(CH3). In some embodiments, Z is O. In some embodiments, Z is S. In some embodiments, M is CR5R6and Z is CR9R10. In some embodiments, M is CR5R6and Z is NR12. In some embodiments, M is CR5R6and Z is O. In some embodiments, M is CR5R6and Z is S. In some embodiments, M is NR11and Z is O. In some embodiments, M is NR11and Z is S. In some embodiments, M is NR11and Z is CR9R10. In some embodiments, M is O and Z is NR12. In some embodiments, M is O and Z isCR10R9.In some embodiments, M is S and Z is CR9R10. In some embodiments, M is Oand Z is O. In some embodiments, M is S and Z is O.In some embodiments, Q is CH2, T is CH2, and X is absent. In some embodiments, Q is CH2, T is C(CH3)2, and X is absent. P7162PC00 52 In some embodiments, M is CH2, Q is CH2, T is CH2or C(CH3)2, and X is absent. In some embodiments, M is O, Q is CH2, T is CH2, and X is absent. In some embodiments, M is S, Q is CH2, T is CH2, and X is absent. In some embodiments, Q isC(CH3)2, T is CH2, and X is absent. In some embodiments, M is N(CH3), Q is CH2, T isCH2, and X is absent. In some embodiments, M is CH2, Q is CH2, T is CH2, and X is absent. In some embodiments, R1is selected from the group consisting of H; F; Cl; Br; C1-3alkyl optionally substituted with one or more, identical or different, substituents R13; and-OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14. In some embodiments, R1is selected from the group consisting of H; F; Cl; Br; and -OC1-3alkyl optionally substituted with one or more, identical or different, substituentsR14. In some embodiments, R1 is H. In some embodiments, R1 is F. In someembodiments, R1 is Cl. In some embodiments, R1 is Br. In some embodiments, R1 isC1-3 alkyl substituted with one or more, identical or different, substituents R13. In someembodiments, R1 is C1-3 alkyl. In some embodiments, R1 is C2-3 alkenyl substituted withone or more, identical or different, substituents R13. In some embodiments, R1 is C2-3alkenyl In some embodiments, R1 is -OC1-3 alkyl. In some embodiments, R1 is -OCH3.In some embodiments, R1 is -OCH2CH3. In some embodiments, R1 is -OC1-3 alkylsubstituted with one or more, identical or different, substituents R14. In some embodiments, R1is-OC3-5 cycloalkyl. In some embodiments, R1is-OC3-5 cycloalkyl substituted with one or more, identical or different, substituents R14. In someembodiments, R1 is -SC1-3 alkyl. In some embodiments, R1 is -SC1-3 alkyl substitutedwith one or more, identical or different, substituents R14.In some embodiments, R1isSC3-5 cycloalkyl. In some embodiments, R1 is SC3-5 cycloalkyl substituted with one ormore, identical or different, substituents R14. In some embodiments, R1 is selected fromthe group consisting of H; F; Cl; Br; CH3; -OCH3; and -OCH2CH3.In some embodiments, R2is selected from the group consisting of F; Cl; Br; and C1-3 alkyl optionally substituted with one or more, identical or different, substituents R14. Insome embodiments, R2 is F. In some embodiments, R2 is Cl. In some embodiments, R2is Br. In some embodiments, R2 is C1-3 alkyl. In some embodiments, R2 is C1-3 alkylsubstituted with one or more, identical or different, substituents R14. In someembodiments, R2 is CH3.In some embodiments, R2 is C3 cycloalkyl. In someembodiments, R2 is C3 cycloalkyl substituted with one or more, identical or different, P7162PC00 53substituents R14. In some embodiments, R2 is selected from the group consisting of F;Cl; Br; C1-3alkyl, and C3cycloalkyl. In some embodiments, R1is linked to R2to form a ring together with the intervening atoms. In some embodiments, R1is C1-3alkanediyl. In some embodiments, R1is C1-3alkanediyl substituted with one or more, identical or different, substituents R13. In someembodiments, R1is -O-C1-3alkanediyl. In some embodiments, R1is -O-C1-3alkanediyl substituted with one or more, identical or different, substituents R13. In some embodiments, R2is C1-3alkanediyl. In some embodiments, R2is C1-3alkanediyl substituted with one or more, identical or different, substituents R13.In some embodiments, R3 is H. In some embodiments, R3 is F. In some embodiments,R3 is Cl.In some embodiments, R1is selected from the group consisting of H; F; Cl and OMeand R2 is selected from the group consisting of F and Cl. In some embodiments, R1 isselected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13; and -OC1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14; R2 is selected fromthe group consisting of F; Cl; Br; C1-3 alkyl optionally substituted with one or more, identical or different, substituents R14and C3 cycloalkyl optionally substituted with oneor more, identical or different, substituents R14; and R3 is H or F. In some embodiments,R1 is selected from the group consisting of H; F; Cl; Br; CH3; -OCH3; and -OCH2CH3; R2is selected from the group consisting of F; Cl; Br; C1-3 alkyl, and C3 cycloalkyl; and R3isH. In some embodiments, R1 is selected from the group consisting of H, F, Cl, Br, and -OC1-3 alkyl optionally substituted with one or more, identical or different, substituentsR14; R2 is selected from the group consisting of F, Cl, Br, and C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14; R3 is H; and R14 isindependently selected from the group consisting of deuterium and F. Compounds of the invention also include tautomeric forms. Below are exemplary tautomeric forms of a few R4moieties of the compounds disclosed herein: P7162PC00 54 . ,wherein R20 is H, deuterium or F. In some embodiments, R4 ,wherein R20 is H, deuterium or F. In some , whereinR20 is H, deuterium or F. In some , wherein R20is H, deuterium or F. In some embodiments, R4is P7162PC00 55 . In some embodiments, R4, wherein R20 is H, deuterium or F. In some embodiments, R4 is, wherein R20is H, deuterium or F. In some embodiments, R4is , wherein R20is H, deuterium or F. In some embodiments, R4 is , wherein R20 is H, deuterium or F.In some embodiments, R20 is H. In some embodiments, R20 is deuterium. In someembodiments, R20 is F.In some embodiments, R5 is H. In some embodiments, R5 is selected from the groupconsisting of H; deuterium; F; and C1-3 alkyl optionally substituted with one or more,identical or different, substituents R13. In some embodiments, R5 is deuterium.In some embodiments, R5 is F. In some embodiments, R5 is C1-3 alkyl. In someembodiments, R5 is C1-5 alkyl substituted with one or more, identical or different,substituents R13. In some embodiments, R5 is C1-3 alkyl substituted with one or more,identical or different, substituents R13. In some embodiments, R5 is C3-5 cycloalkyl.In some embodiments, R5 is C3-5 cycloalkyl substituted with one or more, identical ordifferent, substituents R13. In some embodiments, R5 is C1-3 alkyl substituted with R15.In some embodiments, R5 is selected from the group consisting of H; deuterium; and F.In some embodiments, R6 is H. In some embodiments, R6 is deuterium. In someembodiments, R6 is F. In some embodiments, R6 is C1-3 alkyl. In some embodiments, P7162PC00 56R6 is CH3. In some embodiments, R6 is C1-3 alkyl substituted with one or more, identicalor different, substituents R13. In some embodiments, R6 is selected from the groupconsisting of H; deuterium; and F.In some embodiments, R7 is H. In some embodiments, R7 is deuterium. In someembodiments, R7 is F. In some embodiments, R7 is C1-3 alkyl. In some embodiments,R7 is CH3. In some embodiments, R7 is C1-3 alkyl substituted with one or more, identicalor different, substituents R13. In some embodiments, R7 is selected from the groupconsisting of H; deuterium; F; and Me.In some embodiments, R8 is H. In some embodiments, R8 is deuterium. In someembodiments, R8 is F. In some embodiments, R8 is C1-3 alkyl. In some embodiments,R8 is CH3. In some embodiments, R8 is C1-3 alkyl substituted with one or more, identicalor different, substituents R13. In some embodiments, R8 is selected from the groupconsisting of H; deuterium; F; and Me.In some embodiments, R9 is H. In some embodiments, R9 is deuterium. In someembodiments, R9 is F. In some embodiments, R9 is C1-3 alkyl. In some embodiments,R9 is CH3. In some embodiments, R9 is C1-3 alkyl substituted with one or more, identicalor different, substituents R13. In some embodiments, R9 is selected from the groupconsisting of H, deuterium, F, and C1-3 alkyl substituted with one or more, identical ordifferent, substituents R13. In some embodiments, R9 is selected from the groupconsisting of H, deuterium, F, and C1-3 alkyl.In some embodiments, R10 is H. In some embodiments, R10 is deuterium. In someembodiments, R10 is F. In some embodiments, R10 is C1-3 alkyl. In some embodiments,R10 is C1-3 alkyl substituted with one or more, identical or different, substituents R13.In some embodiments, R10 is C3-5 cycloalkyl. In some embodiments, R10 is C3-5cycloalkyl substituted with one or more, identical or different, substituents R13. In someembodiments, R10 is C1-3 alkyl substituted with R16. In some embodiments, R10 isselected from the group consisting of H, deuterium, F, and C1-3 alkyl.In some embodiments, R11 is H or C1-3 alkyl optionally substituted with one or more,identical or different, substituents R13. In some embodiments, R11 is H. In someembodiments, R11 is C1-3 alkyl. In some embodiments, R11 is CH3. In some P7162PC00 57 embodiments, R11 is C1-3 alkyl substituted with one or more, identical or different,substituents R13. In some embodiments, R11 is C3-5 cycloalkyl. In some embodiments,R11 is C3-5 cycloalkyl substituted with one or more, identical or different, substituentsR13. In some embodiments, R11 is C1-3 alkyl substituted with R15. In some embodiments,R11 is H or Me.In some embodiments, R12 is H. In some embodiments, R12 is C1-3 alkyl. In someembodiments, R12 is methyl. In some embodiments, R12 is ethyl. In some embodiments,R12 is propyl. In some embodiments, R12 is propyl, such as n-propyl or isopropyl. Insome embodiments, R12 is butyl, such as isobutyl. In some embodiments, R12 is pentyl,such as isopentyl. In some embodiments, R12 is C1-3 alkyl substituted with one or more, identical ordifferent, substituents R13. In some embodiments, R12 is C1-3 alkyl substituted with oneor more, identical or different, substituents R13 wherein R13 is -OC1-3 alkyl. In someembodiments, R12 is C2 alkyl substituted with -OC1-3 alkyl. In some embodiments, R12 is-(CH2)2OCH3, -(CH2)2OCH2CH3, -(CH2)2OCH(CH3)2. In some embodiments, R12 is C1-3 alkyl substituted with one or more, identical ordifferent, substituents R13wherein R13is -OC3-5 cycloalkyl. In some embodiments, R12 .In some embodiments, R12 is C3-5 cycloalkyl. In some embodiments, R12 is C3-5cycloalkyl substituted with one or more, identical or different, substituents R13. In some embodiments, R12 is C1-3 alkyl substituted with R16. In some embodiments, R12 is C1alkyl substituted with R16. In some embodiments, R12is selected from the group consisting of: , P7162PC00 58 In some embodiments, R12is selected from the group consisting of: , In some embodiments, R12is selected from the group consisting of: . In some embodiments, R12 is C1-3 alkyl substituted with one or more F. In someembodiments, R12 is -CH2CH2F, -CH2CHF2. In some embodiments, R12 is -(CH2)3CH2F In some embodiments, wherein R5is linked to R6, R9, R10, or R12to form a ring together with the intervening atom(s). When R5 is linked to R6, R9, R10 or R12 to form a ring, thenR5 is C1-3 alkanediyl optionally substituted with one or more, identical or different,substituents R13. In some embodiments, R5 is C1-3 alkanediyl. In some embodiments,R5 is C1-3 alkanediyl substituted with one or more, identical or different, substituentsR13. In some embodiments, R5is linked to R6to form a ring together with the intervening atom. In some embodiments, R5is linked to R9to form a ring together with the intervening atoms. In some embodiments, R5is linked to R10to form a ring together with the intervening atoms. In some embodiments, R5is linked to R12to form a ring together with the intervening atoms. P7162PC00 59 In some embodiments, R6is linked to R5, R9, R10or R12to form a ring together with theintervening atom(s). When R6 is linked to R5, R9, R10 or R12 to form a ring, then R6 is C1-3 alkanediyl optionally substituted with one or more, identical or different, substituentsR13. In some embodiments, R6 is C1-3 alkanediyl. In some embodiments, R6 is C1-3alkanediyl substituted with one or more, identical or different, substituents R13. In someembodiments, R6is linked to R9to form a ring together with the intervening atoms. In some embodiments, R6is linked to R10to form a ring together with the intervening atoms. In some embodiments, R6is linked to R12to form a ring together with the intervening atoms. In some embodiments, R7is linked to R8to form a ring together with the interveningatom(s). When R7 is linked to R8 to form a ring, then R7 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13, and R8is C1-3alkanediyl optionally substituted with one or more, identical or different, substituentsR13. In some embodiments, R7 is C1-3 alkanediyl. In some embodiments, R7 is C1-3alkanediyl substituted with one or more, identical or different, substituents R13. In someembodiments, R8 is C1-3 alkanediyl. In some embodiments, R8 is C1-3 alkanediylsubstituted with one or more, identical or different, substituents R13.In some embodiments, R9 is linked to R5, R6, R10 or R11 to form a ring together with theintervening atom(s). When R9 is linked to R5, R6, R10 or R11 to form a ring, then R9 is C1-3 alkanediyl optionally substituted with one or more, identical or different, substituentsR13. In some embodiments, R9 is C1-3 alkanediyl. In some embodiments, R9 is C1-3alkanediyl substituted with one or more, identical or different, substituents R13. In someembodiments, R9is linked to R10to form a ring together with the intervening atoms. In some embodiments, R9is linked to R11to form a ring together with the intervening atoms. In some embodiments, R10is linked to R5, R6, R9or R11to form a ring together with the intervening atom(s). When R10is linked to R5, R6, R9or R11, then R10is C1-3 alkanediyl optionally substituted with one or more, identical or different, substituents R13. In someembodiments, R10 is C1-3 alkanediyl. In some embodiments, R10 is C1-3 alkanediylsubstituted with one or more, identical or different, substituents R13. In some embodiments, R10is linked to R11to form a ring together with the intervening atom. P7162PC00 60In some embodiments, R11 is linked to R9, R10, or R12 to form a ring together with theintervening atoms. When R11 is linked to R9, R10, or R12, then R11 is C1-3 alkanediyloptionally substituted with one or more, identical or different, substituents R13. In someembodiments, R11 is C1-3 alkanediyl. In some embodiments, R11 is C1-3 alkanediylsubstituted with one or more, identical or different, substituents R13. In some embodiments, R11is linked to R12to form a ring together with the intervening atoms.In some embodiments, R12 is linked to R5, R6, or R11 to form a ring together with theintervening atom(s). when R12 is linked to R5, R6, or R11, then R12 is C1-3 alkanediyloptionally substituted with one or more, identical or different, substituents R13. In someembodiments, R12 is C1-3 alkanediyl. In some embodiments, R12 is C1-3 alkanediylsubstituted with one or more, identical or different, substituents R13.In some embodiments, R13 is deuterium. In some embodiments, R13 is F. In someembodiments, R13 is Cl. In some embodiments, R13 is CN. In some embodiments, R13is -OC1-3 alkyl. In some embodiments, R13 is -OCH3. In some embodiments, R13 is -OC3-5 cycloalkyl.In some embodiments, R14 is independently selected from the group consisting ofdeuterium, F, and Cl. In some embodiments, R14 is deuterium. In some embodiments,R14 is F. In some embodiments, R14 is deuterium or F. In some embodiments, R14 is Cl.In some embodiments, R14 is CN.In some embodiments, R15 is C3-5 cycloalkyl. In some embodiments, R15 is C3-5cycloalkyl substituted with one or more, identical or different, substituents R13. In someembodiments, R15 is phenyl. In some embodiments, R15 is phenyl substituted with oneor more, identical or different, substituents R17. In some embodiments, R15 is a 5-membered heteroaryl. In some embodiments, R15 is a 5-membered heteroarylsubstituted with one or more, identical or different, substituents R17. In some embodiments, R16is independently selected from the group consisting of - C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more,identical or different, substituents R17, 5- to 10-membered heterocycle optionally P7162PC00 61substituted with one or more, identical or different, substituents R19, 5- to 10-memberedheteroaryl optionally substituted with one or more, identical or different, substituentsR17, and C5-8 bicycloalkyl. In some embodiments, R16 is independently selected fromthe group consisting of -C3-5 cycloalkyl optionally substituted with one or more, identicalor different, substituents R13, C6-10aryl optionally substituted with one or more, identicalor different, substituents R17, 5- to 10-membered heterocycle optionally substituted withone or more, identical or different, substituents R19, and 5- to 10-membered heteroaryloptionally substituted with one or more, identical or different, substituents R17. In someembodiments, R16 is -C(=O)N(R18)2. In some embodiments, R16 is -NR18-C(=O)-R18. Insome embodiments, R16 is -NR18-SO2-R18. In some embodiments, R16 is -SO2-N(R18)2.In some embodiments, R16 is -SO2-R18. In some embodiments, R16 is -C(=O)-R18. Insome embodiments, R16 is -OR18. In some embodiments, R16 is -SR18. In someembodiments, R16 is -OCH2R18. In some embodiments, R16 is C1-3 alkyl optionallysubstituted with one or more F. In some embodiments, R16 is -CF3, -CHF2, or -CH2F. Insome embodiments, R16 is -C3-5 cycloalkyl. In some embodiments, R16 is cyclobutyl. Insome embodiments, R16 is cyclopropyl. In some embodiments, R16 is cyclopropyloptionally substituted with one or more F. In some embodiments, R16 is cyclobutyloptionally substituted with one or more F. In some embodiments, R16 is -C3-5 cycloalkylsubstituted with one or more, identical or different, substituents R13. In someembodiments, R16 is C6-10 aryl. In some embodiments, R16 is phenyl. In someembodiments, R16 is C6-10 aryl substituted with one or more, identical or different,substituents R17.In some embodiments, the C6-10 aryl is phenyl. In some embodiments, R16 is phenylsubstituted with one or more, identical or different, substituents R17. In someembodiments, R16 is phenyl substituted with one or more, identical or different,substituents selected from the group consisting of methoxy, methyl and F. In someembodiments, R16 is a 5- to 10-membered heterocycle. In some embodiments, R16 is a5- to 10-membered heterocycle substituted with one or more, identical or different,substituents R19. In some embodiments, R16 is a 5- to 10-membered heteroaryl. Insome embodiments, R16 is a 5- to 10-membered heteroaryl substituted with one ormore, identical or different, substituents R17. In some embodiments, R16 is a 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl is a 6-memberedheteroaryl. In some embodiments, R16 is a 5- to 10-membered heteroaryl and the 5- to10-membered heteroaryl is a 5-membered heteroaryl. In some embodiments, R16 is a5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl is selected from P7162PC00 62 the group consisting of thiophenyl, furanyl, oxazolyl, and isoxazolyl. In someembodiments, R16 is thiophenyl. In some embodiments, R16 is furanyl.In someembodiments, R16 is oxazolyl. In some embodiments, R16 is isoxazolyl. In someembodiments, R16 is C5-8 bicycloalkyl. In some embodiments, R16 isbicyclo[1.1.1]pentyl. In some embodiments, R16is independently selected from the group consisting of -OR18, -SR18, -OCH2R18, C1-3alkyl optionally substituted with one or more F, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17, and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17. In some embodiments, R16is independently selected from the group consisting of -OR18, -OCH2R18, C1-3alkyl optionally substituted with one or more F, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical ordifferent, substituents R17, and 5- to 6-membered heteroaryl optionally substituted withone or more, identical or different, substituents R17.In some embodiments, R17 is independently selected from the group consisting ofdeuterium, methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H,CFH2, CD3, cyclopropyl, cyano, Cl, Br, and F. In some embodiments, R17 is deuterium.In some embodiments, R17 is methoxy. In some embodiments, R17 is -OCF3. In someembodiments, R17 is OCF2Cl. In some embodiments, R17 is OCF2H. In someembodiments, R17 is OCFH2. In some embodiments, R17 is OCD3. In someembodiments, R17 is methyl. In some embodiments, R17 is CF3. In some embodiments,R17 is CF2Cl. In some embodiments, R17 is CF2H. In some embodiments, R17 is CFH2.In some embodiments, R17 is CD3. In some embodiments, R17 is cyclopropyl.In some embodiments, R17 is NH2. In some embodiments, R17 is -NHAc. In someembodiments, R17 is -C(=O)-NH2. In some embodiments, R17 is nitro. In someembodiments, R17 is CN. In some embodiments, R17 is Cl. In some embodiments, R17is Br. In some embodiments, R17is F. In some embodiments, R18is independently selected from the group consisting ofdeuterium, F, Cl, CN, C1-3 alkyl, and C3-5 cycloalkyl. In some embodiments, R18 isdeuterium. In some embodiments, R18 is F. In some embodiments, R18 is Cl. In someembodiments, R18 is CN. In some embodiments, R18 is C1-3 alkyl optionally substitutedwith one or more F. In some embodiments, R18 is C3-5 cycloalkyl. P7162PC00 63In some embodiments, R16 is a 5- to 10-membered heterocycle substituted with one ormore, identical or different, substituents R19. In some embodiments, R19is independently selected from the group consisting of deuterium, methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl,cyano, Cl, Br, and F. In some embodiments, R19 is deuterium. In some embodiments,R19 is methoxy. In some embodiments, R19 is -OCF3. In some embodiments, R19 isOCF2Cl. In some embodiments, R19 is OCF2H. In some embodiments, R19 is OCFH2. Insome embodiments, R19 is OCD3. In some embodiments, R19 is methyl. In someembodiments, R19 is CF3. In some embodiments, R19 is CF2Cl. In some embodiments,R19 is CF2H. In some embodiments, R19 is CFH2. In some embodiments, R19 is CD3. Insome embodiments, R19 is cyclopropyl. In some embodiments, R19 is NH2. In someembodiments, R19 is -NHAc. In some embodiments, R19 is -C(=O)-NH2. In someembodiments, R19 is nitro. In some embodiments, R19 is CN. In some embodiments,R19is Cl. In some embodiments, R19is Br. In some embodiments, R19is F. In someembodiments, R19 is =O. When R16 is a 5- to 10-membered heterocycle substitutedwith one or more, identical or different, substituents R19, and R19is =O, it is to be understood that two hydrogens bound to the same carbon atom of the heterocycle are replaced with =O. In some embodiments, M is CH2, Q is CH2, T is CH2, X is absent, and Z is CH2. In some embodiments, M is CH2, Q is CH2, T is CH2, X is absent, and Z is O. In some embodiments, M is CH2, Q is CH2, T is CH2, X is absent, and Z is S. In some embodiments, M is CH2, Q is CH2, T is C(CH3)2, X is absent, and Z is O. In some embodiments, M is CH2, Q is C(CH3)2, T CH2, is X is absent, and Z is O. In some embodiments, M is O, Q is CH2, T is CH2, X is absent, and Z is CH2. In someembodiments, M is O, Q is CH2, T is CH2, X is absent, and Z is O. In someembodiments, M is S, Q is CH2, T is CH2, X is absent, and Z is CH2. In someembodiments, M is S, Q is CH2, T is CH2, X is absent, and Z is O. In someembodiments, M is O, Q is CH2, T is CH2, X is absent, and Z is NR12. In someembodiments, M is O, Q is C(CH3)2, T CH2, is X is absent, and Z is NR12. In some embodiments, M is O, Q is CH2, T is C(CH3)2, X is absent, and Z is NR12. In some embodiments, M is CH2, Q is CH2, T is CH2, X is absent, and Z is NR12. In some embodiments, M is CH2, Q is CH2, T is CH2, X is absent, and Z is NH. In some embodiments, M is CH2, Q is CH2, T is CH2, X is absent, and Z is NCH3. In some P7162PC00 64 embodiments, M is CH2, Q is CH2, T is CH2, X is absent, and Z is CF2. In some embodiments, M is NR11, Q is CH2, T is CH2, X is absent, and Z is O. In some embodiments, M is NCH3, Q is CH2, T is CH2, X is absent, and Z is O. In someembodiments, M is NR11,Q is CH2, T is CH2, X is CH2, and Z is CH2. In someembodiments, M is NCH3, Q is CH2, T is CH2, X is CH2, and Z is CH2. In someembodiments, M is NR11, Q is CH2, T is CH2, X is absent, and Z is S. In some embodiments, M is NCH3, Q is CH2, T is CH2, X is absent, and Z is S. In some embodiments, the compound is 5-(6-chloro-7-fluoro-8-chromanyl)-1,3- oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7- fluoro-8-chromanyl)-1,3-thiazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, thecompound is 5-(3-chloro-2-fluoro-5,6,7,8-tetrahydro-1-naphthyl)-1,3-thiazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(2-chloro-3-fluoro-5,6,7,8- tetrahydro-1-naphthyl)-1,3-thiazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-fluoro-2,2-dimethyl-8-chromanyl)-1,3-thiazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-methoxy-8-chromanyl)-1,3- thiazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(4-benzyl-7- chloro-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-fluoro-5-chromanyl)-1,3- thiazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7- methoxy-8-chromanyl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(3-chloro-2-methoxy-5,6,7,8-tetrahydro-1-naphthyl)-1,3-oxazolidine-2,4- dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-fluoro-3,4-dihydro-2H- 1-benzothiin-8-yl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the P7162PC00 65 compound is 5-(7-chloro-6-fluoro-5-chromanyl)-1,3-thiazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{10-chloro-9-methoxybicyclo[5.4.0]undeca- 1(11),7,9-trien-8-yl}-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-6-methoxy-3,4-dihydro-2H-1-benzothiin-5-yl)-1,3-oxazolidine- 2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-methoxy-3,4- dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-ethoxy-3,4-dihydro-2H-1-benzothiin-8-yl)- 1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(3-chloro-8,8- difluoro-2-methoxy-5,6,7,8-tetrahydro-1-naphthyl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(3-chloro-2-ethoxy-5,6,7,8-tetrahydro-1- naphthyl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(3- chloro-5,6,7,8-tetrahydro-1-naphthyl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(2-chloro-3-fluoro-5,6,7,8-tetrahydro-1-naphthyl)-1H- tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(3-chloro-2-fluoro-5,6,7,8- tetrahydro-1-naphthyl)-1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5- (2,3-dichloro-5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-6-fluoro-8-chromanyl)-1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(3-chloro-2-methoxy-5,6,7,8-tetrahydro-1- naphthyl)-1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(2,3-difluoro- 5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(3-fluoro-2-methyl-5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole, or a P7162PC00 66 pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-methoxy-4-methyl-3,4-dihydro-2H- 1,4-benzoxazin-8-yl)-1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7- chloro-6-fluoro-3,4-dihydro-2H-1-benzothiin-8-yl)-1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-6-fluoro-3,4-dihydro-2H-1-benzothiin-5-yl)- 1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-fluoro-2,2- dimethyl-8-chromanyl)-1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(4- benzyl-7-chloro-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-fluoro-8-chromanyl)-1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7-chloro-6-fluoro-4-[(p-fluorophenyl)methyl]- 3,4-dihydro-2H-1,4-benzoxazin-5-yl}-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7-chloro-6-fluoro-4-[(3-thienyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin- 5-yl}-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7-chloro-4- (cyclobutylmethyl)-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7-chloro-6-fluoro-4-[(p- methoxyphenyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7-chloro-6-fluoro-4-(2-methoxyethyl)-3,4- dihydro-2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-6-fluoro-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-6-fluoro-4-propyl- 3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{10-chloro-9-methoxybicyclo[5.4.0]undeca-1(7),8,10-trien-8-yl}-2H- P7162PC00 67 tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7-chloro-6-fluoro-4-[(o- tolyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-methoxy-3,4-dihydro-2H-1-benzothiin-8- yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7-chloro-6-fluoro-4-[(3- furyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(3-chloro-2-ethoxy-5,6,7,8-tetrahydro-1-naphthyl)- 2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-fluoro-1,2,3,4- tetrahydro-8-quinolyl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6- chloro-7-fluoro-3,4-dihydro-2H-1-benzothiin-8-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-fluoro-1-methyl-1,2,3,4-tetrahydro-8- quinolyl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7-chloro-6- fluoro-4-[(1,3-oxazol-4-yl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-6-fluoro-3,4-dihydro-2H-1,4- benzoxazin-5-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7- chloro-6-fluoro-4-[(3-isoxazolyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}-2H- tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7-chloro-6-fluoro-4-[(3- pyridyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-methoxy-8-chromanyl)-2H- tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(4-{(bicyclo[1.1.1]pent-1- yl)methyl}-7-chloro-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7-chloro-4-(cyclopropylmethyl)-6-fluoro-3,4- P7162PC00 68 dihydro-2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-methoxy-1,2,3,4-tetrahydro-8-quinolyl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-methoxy-1-methyl-1,2,3,4- tetrahydro-8-quinolyl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7- chloro-4-[2-(cyclopropylmethoxy)ethyl]-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl}- 2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 3-(6-chloro-7-fluoro-8- chromanylthio)-1H-1,2,4-triazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 3-(6- chloro-7-methoxy-8-chromanylthio)-1H-1,2,4-triazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 4-(6-chloro-7-fluoro-8-chromanyl)-1,2,5-thiadiazol-3-ol, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7-chloro-6-fluoro-4-[(5-methyl-3- isoxazolyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7-chloro-6-fluoro-4-(2-fluoroethyl)-3,4-dihydro- 2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[6- chloro-1-(2-fluoroethyl)-7-methoxy-1,2,3,4-tetrahydro-8-quinolyl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7-chloro-6-fluoro-4-(2-isopropoxyethyl)-3,4- dihydro-2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7-chloro-6-fluoro-4-(2-trifluoromethoxyethyl)-3,4-dihydro-2H-1,4- benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7- chloro-4-propyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7-chloro-4-(cyclopropylmethyl)-3,4-dihydro- 2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7- P7162PC00 69 chloro-4-(cyclobutylmethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7-chloro-4-[(p-fluorophenyl)methyl]-3,4- dihydro-2H-1,4-benzoxazin-5-yl}-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7-chloro-4-(2,2-difluoroethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7-chloro-4-(2- methoxyethyl)-2,2-dimethyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7-chloro-4-(2,2-difluoroethyl)-6-fluoro-3,4- dihydro-2H-1,4-benzoxazin-5-yl]-1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-6-fluoro-4-isopentyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7-chloro-4-[(2,4- difluorophenyl)methyl]-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl}-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7-chloro-4-(2-ethoxyethyl)-6-fluoro-3,4- dihydro-2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-6-fluoro-4-isobutyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7-chloro-6-fluoro-4-(4- fluorobutyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7-chloro-6-fluoro-4-(4,4,4-trifluorobutyl)-3,4-dihydro- 2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7- chloro-4-(2-cyclopropoxyethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7-chloro-6-fluoro-4-[(3-fluoro-4- methoxyphenyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7-chloro-6-fluoro-4-[(4-fluoro-2-tolyl)methyl]- P7162PC00 70 3,4-dihydro-2H-1,4-benzoxazin-5-yl}-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-4-{[p-(difluoromethyl)phenyl]methyl}-6-fluoro-3,4-dihydro-2H- 1,4-benzoxazin-5-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-{7- chloro-6-fluoro-4-[(m-fluorophenyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}-2H- tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-4-isobutyl-3,4- dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-4-isopropyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-3,3-dimethyl-4- methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-6-fluoro-5-chromanyl)-1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-4-methyl-3,4-dihydro-2H-1,4- benzoxazin-8-yl)-1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[4- (cyclopropylmethyl)-7-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[4-(cyclobutylmethyl)-7-fluoro-3,4-dihydro-2H- 1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7- fluoro-4-isobutyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[4-(2,2-difluoroethyl)-7-fluoro-3,4-dihydro-2H- 1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(4- benzyl-7-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(4-benzyl-7-methyl-3,4-dihydro-2H-1,4- benzoxazin-5-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[4- P7162PC00 71 (cyclobutylmethyl)-7-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(4-isobutyl-7-methyl-3,4-dihydro-2H-1,4- benzoxazin-5-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[6- chloro-1-(cyclopropylmethyl)-1,2,3,4-tetrahydro-8-quinolyl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-1-isobutyl-1,2,3,4-tetrahydro-8- quinolyl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[4- (cyclopropylmethyl)-7-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[6-chloro-1-(2,2-difluoroethyl)-1,2,3,4- tetrahydro-8-quinolyl]-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6- chloro-2,3-dihydro-1,4-benzoxathiin-8-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-4-methyl-3,4-dihydro-2H-1,4-benzothiazin- 8-yl)-1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-1- methyl-1,2,3,4-tetrahydro-5-quinolyl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-3,4-dihydro-2H-1-benzothiin-5-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-fluoro-3,3-dimethyl-4-methyl-3,4-dihydro- 2H-1,4-benzoxazin-5-yl)-1H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7- fluoro-4-propyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-fluoro-1-methyl-1,2,3,4-tetrahydro- 8-quinolyl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-[7- chloro-4-(cyclopropylmethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-1,3-oxazolidine-2,4- dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-7-methoxy-1-methyl- P7162PC00 72 1,2,3,4-tetrahydro-8-quinolyl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5- yl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6- chloro-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-6-fluoro-4-methyl-3,4-dihydro-2H-1,4- benzoxazin-5-yl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-6-fluoro-8-chromanyl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6,7-dichloro-3,4-dihydro-2H-1-benzothiin-8- yl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7- chloro-3,3-dimethyl-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-1,3-oxazolidine-2,4- dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-6-fluoro-5-chromanyl)- 1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-bromo-3,4- dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-methyl-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph,tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-5- chromanyl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6- fluoro-7-methyl-5-chromanyl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6-chloro-4-methyl-3,4-dihydro-2H-1,4-benzothiazin- 8-yl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6- chloro-2,3-dihydro-1,4-benzoxathiin-8-yl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-6-methoxy-5-chromanyl)-1,3- P7162PC00 73 oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(6,7-difluoro-5- chromanyl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7- chloro-6-fluoro-3,4-dihydro-2H-1-benzothiin-5-yl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In some embodiments, the compound is 5-(7-chloro-6-fluoro-2,3-dihydro-1,4-benzodioxin- 5-yl)-1,3-oxazolidine-2,4-dione, or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. In one embodiment, the compound or the compound for use according to the presentdisclosure has been modified in order to increase its half-life when administered to apatient, in particular its plasma half-life. In one embodiment, the compound or thecompound for use according to the present disclosure further comprises a moietyconjugated to said compound, thus generating a moiety-conjugated compound. In one embodiment, said moiety-conjugated compound has a plasma and / or serum half-life being longer than the plasma and / or serum half-life of the non-moiety conjugatedcompound. In one embodiment, the moiety conjugated to the compound or compoundfor use according to the present disclosure, is one or more type(s) of moieties selectedfrom the group consisting of albumin, fatty acids, polyethylene glycol (PEG), acylation groups, antibodies and antibody fragments. In one embodiment, the compound has activity on the ClC-1 receptor. In one embodiment, the compound is an inhibitor of the ClC-1 ion channel. In one embodiment, the compound is capable of improving the recovered force in isolated rat soleus muscles after exposure to tubocurarine. In one embodiment, the recovery of force in muscles with neuromuscular dysfunction is >5%, for example >10%, for example >15%, for example >20%, for example >25%, for example >30% and for example >35%. Neuromuscular disorders The compound or compound for use of the present disclosure may be used for treating, ameliorating and / or preventing a neuromuscular disorder, or reversing neuromuscular blockade. P7162PC00 74 The inventors of the present disclosure have shown that inhibition of ClC-1 channels strengthens neuromuscular transmission. ClC-1 function may therefore contribute to muscle weakness in conditions of compromised neuromuscular transmission. Thus, in one embodiment of the present disclosure, the compound or the compound for use as described herein inhibits ClC-1 channels. Thus, it is appreciated that compounds and / or compounds for use of Formula (I) inhibit ClC-1 channels. The neuromuscular disorder may also include neuromuscular dysfunctions. Neuromuscular disorders include for example disorders with symptoms of muscle weakness and fatigue. Such disorders may include conditions with reduced neuromuscular transmission safety factor. In one embodiment the neuromuscular disorders are motor neuron disorders. Motor neuron disorders are disorders with reduced safety in the neuromuscular transmission. In one embodiment motor neurondisorders are selected from the group consisting of amyotrophic lateral sclerosis (ALS)(Killian JM, Wilfong AA, Burnett L, Appel SH, Boland D. Decremental motor responses to repetitive nerve stimulation in ALS. Muscle Nerve, 1994, 17, 747-754), spinal muscular atrophy (SMA) (Wadman RI, Vrancken AF, van den Berg LH, van der Pol WL. Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and3. Neurology, 2012, 79, 2050-2055), Charcot-Marie Tooth disease (Bansagi B, GriffinH, Whittaker RG, Antoniadi T, Evangelista T, Miller J, Greenslade M, Forester N, Duff J, Bradshaw A, Kleinle S, Boczonadi V, Steele H, Ramesh V, Franko E, Pyle A, Lochmüller H, Chinnery PF, Horvath R. Genetic heterogeneity of motor neuropathies.Neurology, 2017, 28;88(13):1226-1234), X-linked spinal and bulbar muscular atrophy(Yamada, M., Inaba, A., Shiojiri, T. X-linked spinal and bulbar muscular atrophy with myasthenic symptoms. Journal of the Neurological Sciences, 1997, 146, 183-185), Kennedy´s disorder (Stevic, Z., Peric, S., Pavlovic, S., Basta, I., Lavrnic, D., Myasthenic symptoms in a patient with Kennedy's disorder. Acta Neurologica Belgica, 2014, 114, 71-73), multifocal motor neuropathy (Roberts, M., Willison, H.J., Vincent, A., Newsom-Davis, J. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann Neurol.1995, 38, 111-118), Guillain-Barré syndrome (Ansar, V., Valadi, N. Guillain-Barré Syndrome Prim. Care, 2015, 42, 189-193); poliomyelitis (Trojan, D.A., Gendron, D., Cashman, N.R. Electrophysiology and electrodiagnosis of P7162PC00 75 the post-polio motor unit. Orthopedics, 1991, 14, 1353-1361, and Birk T.J. Poliomyelitisand the post-polio syndrome: exercise capacities and adaptation - current research,future directions, and widespread applicability. Med. Sci. Sports Exerc., 1993, 25, 466-472), post-polio syndrome (Garcia, C.C., Potian, J.G., Hognason, K., Thyagarajan, B.,Sultatos, L.G., Souayah, N., Routh, V.H., McArdle, J.J. Acetylcholinesterase deficiency contributes to neuromuscular junction dysfunction in type 1 diabetic neuropathy. Am. J.Physiol. Endocrinol. Metab., 2012, 15, E551 – 561) and sarcopenia (Gilmore K.J.,Morat T., Doherty T.J., Rice C.L., Motor unit number estimation and neuromuscularfidelity in 3 stages of sarcopenia.201755(5):676-684). In one embodiment, theneuromuscular disorder is diabetic polyneuropathy. In one embodiment, the neuromuscular disorder is sarcopenia. In one embodiment, the neuromuscular disorder is Kennedy´s disorder. In one embodiment, the neuromuscular disorder is multifocal motor neuropathy. Thus, in one embodiment of the present disclosure the neuromuscular disorder is amyotrophic lateral sclerosis (ALS). In another embodiment the neuromuscular disorder is spinal muscular atrophy (SMA). In another embodiment the neuromuscular disorder is Charcot-Marie tooth disease (CMT). In another embodiment the neuromuscular disorder is sarcopenia. In yet another embodiment, the neuromuscular disorder is critical illness myopathy (CIM). As stated above the neuromuscular disorders include for example disorders with symptoms of muscle weakness and fatigue. Such disorder may for example includediabetes (Am. J. Physiol. Endocrinol. Metab., 2012, 15, E551 – 561).In another embodiment the neuromuscular disorders is chronic fatigue syndrome. Chronic fatigue syndrome (CFS) (Fletcher, S.N., Kennedy, D.D., Ghosh, I.R., Misra, V.P., Kiff, K., Coakley, J.H., Hinds, C.J. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit.Care Med.2003, 31, 1012 – 1016) is the common name for a medical conditioncharacterized by debilitating symptoms, including fatigue that lasts for a minimum of six months in adults. CFS may also be referred to as systemic exertion intolerance disorder (SEID), myalgic encephalomyelitis (ME), post-viral fatigue syndrome (PVFS), chronic fatigue immune dysfunction syndrome (CFIDS), or by several other terms. P7162PC00 76 Symptoms of CFS include malaise after exertion; unrefreshing sleep, widespread muscle and joint pain, physical exhaustion, and muscle weakness. In a further embodiment the neuromuscular disorder is a critical illness polyneuropathy (Angelini C. Spectrum of metabolic myopathies. Biochim. Biophys. Acta., 2015, 1852,615 – 621) or CIM (Latronico, N., Bolton, C.F. Critical illness polyneuropathy andmyopathy: a major cause of muscle weakness and paralysis. Lancet Neurol.2011, 10, 931-941). Critical illness polyneuropathy and CIM are overlapping syndromes of widespread muscle weakness and neurological dysfunction developing in critically ill patients. The neuromuscular disorder may also include metabolic myopathy (Milone, M., Wong,L.J. Diagnosis of mitochondrial myopathies. Mol. Genet. Metab., 2013, 110, 35 – 41)and mitochondrial myopathy (Srivastava, A., Hunter, J.M. Reversal of neuromuscularblock. Br. J. Anaesth.2009, 103, 115 – 129). Metabolic myopathies result from defectsin biochemical metabolism that primarily affects muscle. These may include glycogen storage disorders, lipid storage disorder and 3-phosphocreatine stores disorder. Mitochondrial myopathy is a type of myopathy associated with mitochondrial disorder. Symptoms of mitochondrial myopathies include muscular and neurological problems such as muscle weakness, exercise intolerance, hearing loss and trouble with balance and coordination. Thus, in one embodiment of the present disclosure the neuromuscular disorder is metabolic myopathy. In another embodiment the neuromuscular disorder is periodic paralysis, in particular hypokalemic periodic paralysis which is a disorder of skeletal muscle excitability that presents with recurrent episodes of weakness, often triggered by exercise, stress, or carbohydrate-rich meals (Wu, F., Mi, W., Cannon, S.C., Neurology, 2013, 80, 1110- 1116 and Suetterlin, K. et at, Current Opinion Neurology, 2014, 27, 583-590) or hyperkalemic periodic paralysis which is an inherited autosomal dominant disorder that affects sodium channels in muscle cells and the ability to regulate potassium levels in the blood (Ammat, T. et at, Journal of General Physiology, 2015, 146, 509-525). In an embodiment the neuromuscular disorder is a myasthenic condition. Myasthenic conditions are characterized by muscle weakness and neuromuscular transmissionfailure. Congenital myasthenia syndromes (Finlayson, S., Beeson, D., Palace, J. P7162PC00 77Congenital myasthenic syndromes: an update. Pract. Neurol., 2013, 13, 80 – 91) is aninherited neuromuscular disorder caused by defects of several types at the neuromuscular junction. Myasthenia gravis and Lambert–Eaton syndrome (Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol.2011, 10, 1098-107) are examples of myasthenic conditions. Myasthenia gravis is either an autoimmune or congenital neuromuscular disorder that leads to fluctuating muscle weakness and fatigue. In the most common cases, muscle weakness is caused by circulating antibodies that block ACh receptors at the postsynaptic neuromuscular junction, inhibiting the excitatory effects of the neurotransmitter ACh on nicotinic ACh-receptors at neuromuscular junctions (Gilhus, N.E., Owe, J.F., Hoff, J.M., Romi, F., Skeie, G.O., Aarli, J.A. Myasthenia Gravis: AReview of Available Treatment Approaches, Autoimmune Diseases, 2011, Article ID84739). Lambert–Eaton myasthenic syndrome (also known as LEMS, Lambert–Eaton syndrome, or Eaton–Lambert syndrome) is a rare autoimmune disorder that is characterized by muscle weakness of the limbs. It is the result of an autoimmune reaction in which antibodies are formed against presynaptic voltage-gated calcium channels, and likely other nerve terminal proteins, in the neuromuscular junction. Thirty to fifty percent of patients with acetylcholine receptor (AChR) antibody-negative myasthenia gravis (MG) have antibodies to muscle specific kinase (MuSK) and are referred to as having MuSK-MG (Borges, L.S., Richman, D.P., Muscle-Specific Kinase Myasthenia Gravis, Frontiers in Immunology, 2020, 11:707). . In one embodiment of the present disclosure the neuromuscular disorder is myasthenia gravis. In another embodiment the neuromuscular disorder is autoimmune myasthenia gravis. In another embodiment the neuromuscular disorder is MuSK-MG. In another embodiment the neuromuscular disorder is Lambert–Eaton syndrome. In another embodiment the neuromuscular disorder is seronegative myasthenia gravis. In another embodiment the neuromuscular disorder is congenital myasthenia gravis. X-linked myotubular myopathy is a part of a group of centronuclear myopathies where cell nuclei are abnormally located in the centre of muscle cells instead of their normallocation at the periphery. It is one of the severest congenital muscle diseases and ischaracterized by marked muscle weakness, hypotonia and feeding and breathing difficulties (Dowling JJ, Lawlor MW, Das S. X-Linked Myotubular Myopathy.2002 Feb P7162PC00 78 25 [Updated 2018 Aug 23]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle : University of Washington, Seattle; 1993-2022. Available from: https: / / www.ncbi.nlm.nih.gov / books / NBK1432 / ). In one embodiment the neuromuscular disorder is myotubular myopathy. Duchenne muscular dystrophy is a severe type of muscular dystrophy that primarily affects boys resulting initially in fatigue and muscle weakness (Angelini C, Tasca E,Fatigue in muscular dystrophies, Neuromuscular Disorders, 2012, 22 Suppl 3: S214-20). In one embodiment the neuromuscular disorder is Duchenne muscular dystrophy. Multiple sclerosis (MS) is the most common demyelinating disease, in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. It has been shown that people with multiple sclerosis typically experience greater levels of exercise-induced fatigue compared with healthy individuals (Brotherton et al, J. Neuorophysiol.2022, 128, 105-117). There are four types of MS in what is known as the Lublin classification: clinically isolated syndrome (CIS), relapsing- remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS (SPMS). In one embodiment, the neuromuscular disorder is selected from the group consisting of multiple sclerosis (MS), clinically isolated syndrome (CIS), relapsing- remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS (SPMS). Neuromuscular blockade is used in connection with surgery under general anaesthesia. Reversing agents are used for more rapid and safer recovery of muscle function after such blockade. Complications with excessive muscle weakness after blockade during surgery can result in delayed weaning from mechanical ventilation and respiratory complications after the surgery. These complications can have pronounced effects on outcome of the surgery and future quality of life of patients, there is a need for improved reversing agents (Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects ofresidual neuromuscular block. Anesth Analg.2010111(1):120-8). Thus, in oneembodiment, the neuromuscular disorder has been induced by a neuromuscular blocking agent. In one particular embodiment the neuromuscular disorder is muscle P7162PC00 79 weakness caused by neuromuscular blockade after surgery. In another embodiment of the present disclosure the compound or the compound for use is used for reversing and / or ameliorating neuromuscular blockade after surgery. In one embodiment, the neuromuscular blockade is drug induced. In one embodiment, the neuromuscular blockade is caused by non-depolarizing neuromuscular blocker or antibiotic agent. In one embodiment the neuromuscular blockade is induced by an antibiotic. In one embodiment the neuromuscular blockade is induced by a non-depolarizing neuromuscular blocker. In one embodiment the compound or the compound for use of the present disclosure is used to prevent a neuromuscular disorder. The compound or the compound for use may for example be used prophylactically against nerve gas that is known to cause symptoms of muscle weakness and fatigue (Kawamura, Y., Kihara, M., Nishimoto, K., Taki, M. Efficacy of a half dose of oral pyridostigmine in the treatment of chronic fatigue syndrome: three case reports. Pathophysiology, 2003, 9, 189-194). In one embodiment the compound or the compound for use of the present disclosure may be used in thetreatment of muscle weakness (such as drooping eyelids, loss of facial expression,constipation, muscle weakness in arms, muscle weakness in legs and dyspnoea) caused by botulism poisoning. In one embodiment the compound or the compound for use of the present disclosure may be used in the treatment of snake bites where the snake toxin, such as α-neurotoxin or myotoxin, is known to cause symptoms of muscle weakness and fatigue. In one embodiment, the neuromuscular disorder is selected from the group consisting of myasthenia gravis, autoimmune myasthenia gravis, congenital myasthenia gravis, seronegative myasthenia gravis, muscle specific kinase myasthenia gravis (MuSK- MG), Lambert-Eaton Syndrome, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), critical illness myopathy (CIM), Charcot-Marie Tooth disease, diabetic polyneuropathy, periodic paralysis, hypokalemic periodic paralysis, hyperkalemic periodic paralysis, myotubular myopathy, Duchenne muscular dystrophy, Guillain-Barré syndrome, poliomyelitis, post-polio syndrome, chronic fatigue syndrome, critical illness polyneuropathy, metabolic myopathy, Kennedy´s disorder and multifocal motor neuropathy. P7162PC00 80 Pharmaceutical formulations In one aspect, the present invention relates to a composition comprising the compound as disclosed herein. The composition according to the present disclosure may be used for treating, ameliorating and / or preventing a neuromuscular disorder, and / or for use in reversing and / or ameliorating a neuromuscular blockade. Thus, the compositions and compounds described herein can be pharmaceutically acceptable. In one embodiment the composition as described herein is in the form of a pharmaceutical formulation. In one embodiment, the composition as described herein further comprises apharmaceutically acceptable carrier. In one aspect, the present invention concerns acomposition comprising the compound as defined herein and a pharmaceutically acceptable carrier. Combination therapy The composition of the present disclosure may comprise further active ingredients / agents or other components to increase the efficiency of the composition. Thus, in one embodiment the composition further comprises at least one further active agent. It is appreciated that the active agent can be suitable for treating, preventing or ameliorating said neuromuscular disorder. The active agent in certain embodiments can be an acetylcholine esterase inhibitor. Said acetylcholine esterase inhibitor may for example be selected from the group consisting of delta-9-tetrahydrocannabinol, carbamates, physostigmine, neostigmine, pyridostigmine, ambenonium, demecarium, rivastigmine, phenanthrene derivatives, galantamine, piperidines, donepezil, tacrine, edrophonium, huperzine, ladostigil,ungeremine and lactucopicrin.In certain embodiments, the acetylcholine esterase inhibitor is selected from the group consisting of neostigmine, physostigmine and pyridostigmine. In certain embodiments, the acetylcholine esterase inhibitor is neostigmine or pyridostigmine. The active agent may also be an immunosuppressive drug. Immunosuppressive drugs are drugs that suppress or reduce the strength of the body’s immune system. Immunosuppressive drugs include but are not limited to glucocorticoids, P7162PC00 81 corticosteroids, cytostatics, antibodies and drugs acting on immunophilins. In one embodiment the active agent is prednisone. The active agent may also be an agent that is used in anti-myotonic treatment. Such agents include for example blockers of voltage gated Na+channels, and aminoglycosides. The active agent may also be an agent for reversing a neuromuscular blockade after surgery. Such agents include for example neostigmine or sugammadex (Org 25969, tradename Bridion). The active agent may also be an agent for increasing ACh release by blocking voltage- gated K+channels in the pre-synaptic terminal. Such agent includes 3,4- diaminopyridine (Amifampridine; tradename Firdapse). The active agent may also be an agent for increasing the levels of survival motor neuron (SMN) protein that are produced. For example, by alternating the splicing of the SMN2 gene in order to increase the expression of full-length SMN protein from SMN2 (Zanetta C, Nizzardo M, Simone C, Monguzzi E, Bresolin N, Comi GP, Corti S, "Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials". Clinical Therapeutics, 2014, 36 (1): 128–40). In one embodiment, thecompound that increases the amount of functional SMN protein produced by SMN2 isrisdiplam. In one embodiment, the compound that increases the amount of functional SMN protein produced by SMN2 is nusinersen. In one embodiment, the compound thatincreases the amount of functional SMN protein produced by SMN2 is branaplam. Inone embodiment, the compound that increases the amount of functional SMN proteinproduced by SMN2 is BIIB115.The active agent may be a gene therapy, for example by using viral vectors to deliver the SMN1 transgene to the affected motor neurons, where it leads to an increase in SMN protein production. Such gene therapies include onasemnogene abeparvovec (tradename Zolgensma). The active agent may also be an agent for increasing muscle reactivity. Such agents include skeletal troponin activators such as Tirasemtiv and Reldesemtiv (CK-2127107) P7162PC00 82 (Hwee, D.T., Kennedy, A.R., Hartman, J.J., Ryans, J., Durham, N., Malik, F.I., Jasper, J.R. The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure. Journal of Pharmacology andExperimental Therapeutics, 2015, 353, 159 – 168).The active agent may be antibodies that block the activation of the skeletal muscleprotein myostatin, specifically myostatin inhibitors. Such agents may also be,Apitegromab (SRK-015), GYM329 (RO7204239) or taldefgrobep.The active agent may compounds such as salbutamol, SRK-015, talditercept alfa,taldefgrobep alfa, RG-6237, EXG-001307, biotin, IFB-088, donaperminogeneseltosplasmid, icerguastat, CKD-510, AGT-100216, MiM-111, EN-001, DTx-1252,Ricolinstat, AT-007 (govorestat) and / or ACTX-401.The active agent may be a PMP22 down regulator, such as PXT3003 (a combination of(RS)-baclofen, naltrexone hydrochloride and D-sorbitol). The active agent may also be an agent that disrupts or blocks the IgG-FcRn interaction thereby reducing the overall IgG recycling. Such agents may be antibodies, such as the aglycosylated immunoglobulin (Ig)G1 monoclonal antibody Nipocalimab, or IgG1 Fcfragment such as Efgartigimod alfa (tradename Vyvgart) or a humanized / chimericmonoclonal antibody, such as Rozanolixizumab or a fully human monoclonal antibodysuch as RVT-1401. The active agent may also be an agent that is an inhibitor of the complement component C5a. The active agent may also be an agent that downregulates the overexpression of PMP22 protein, leading to improvement of neuronal signalling indysfunctional peripheral nerves. Such agents may be combination drugs such asPXT3003. Alternatively, the active agent may also be an agent that binds to the protein complement component 5 (C5) and inhibits its cleavage into C5a and C5b. Suchagents may be Zilucoplan (RA101495), Ravulizumab or Eculizumab.The active agent may also be an agent that is a monoclonal antibody medication, suchas Rituximab. P7162PC00 83 Methods In one aspect, the present invention relates to a compound as defined herein for use as a medicament. In one aspect, the present invention relates to a compound as defined herein for use in treating, ameliorating and / or preventing a neuromuscular disorder.In one aspect, the present invention relates to a compound of Formula (I): Formula (I) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;wherein R5 and R6, or R5 and R9, or R5 and R10, or R5 and R12, or R6 and R9, orR6 and R10, or R6 and R12, or R7 and R8, or R9 and R10, or R9 and R11, orR10 and R11, or R11 and R12, are optionally joined together to form a ringtogether with the intervening atom(s); -R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C2-3alkenyl optionally substituted with one or more, identical or different, substituents R13; -OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -OC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; - SC1-3 alkyl optionally substituted with one or more, identical or different, substituents R14and -SC3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R14; and- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and P7162PC00 84 C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14; or R1is linked to R2to form a ring together with the intervening atoms, and R1 is C1-3 alkanediyl optionally substituted with one or more, identical ordifferent, substituents R13, or -O-C1-3 alkanediyl optionally substitutedwith one or more, identical or different, substituents R13, and R2is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:, - R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,or when R5 is linked to R6, R9, R10 or R12 to form a ring, then R5 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R6 is linked to R5, R9, R10 or R12 to form a ring, then R6 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, P7162PC00 85 or when R7 is linked to R8 to form a ring, then R7 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, or when R8 is linked to R7 to form a ring, then R8 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R9 is linked to R5, R6, R10 or R11 to form a ring, then R9 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R10is linked to R5, R6, R9or R11, then R10is C1-3 alkanediyl optionally substituted with one or more, identical or different, substituents R13;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,or when R11 is linked to R9, R10, or R12, then R11 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R12 is linked to R5, R6, or R11, then R12 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl; P7162PC00 86- R14 is independently selected from the group consisting of deuterium, F, Cl,and CN;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8 bicycloalkyl;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F;- R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl;- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof, for use in treating, ameliorating and / or preventing a neuromuscular disorder. P7162PC00 87In one aspect, the present invention relates to a compound as defined herein for use inthe treatment of an indication selected from the group consisting of myasthenia gravis, autoimmune myasthenia gravis, congenital myasthenia gravis, seronegative myasthenia gravis, muscle specific kinase myasthenia gravis (MuSK-MG), Lambert- Eaton Syndrome, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), critical illness myopathy (CIM), Charcot-Marie Tooth disease, diabetic polyneuropathy, periodic paralysis, hypokalemic periodic paralysis, hyperkalemic periodic paralysis, myotubular myopathy, Duchenne muscular dystrophy, Guillain-Barré syndrome, poliomyelitis, post-polio syndrome, chronic fatigue syndrome, critical illness polyneuropathy, metabolic myopathy, Kennedy´s disorder and multifocal motorneuropathy. In one aspect, the present invention relates to a compound as definedherein for use in the symptomatic treatment of sarcopenia. In one aspect, the present invention relates to a compound as defined herein for use in reversing and / or ameliorating a neuromuscular blockade. In one aspect, the present disclosure relates to a method of treating, preventing and / or ameliorating a neuromuscular disorder, said method comprising administering a therapeutically effective amount of the compound or the compound for use as defined herein to a person in need thereof. In one aspect, the present disclosure relates to a method of reversing and / or ameliorating a neuromuscular blockade, said method comprising administering a therapeutically effective amount of the compound or the compound for use as defined herein to a person in need thereof. In one aspect, the present disclosure relates to a method for recovery of neuromuscular transmission, said method comprising administering a therapeutically effective amount of the compound or the compound for use as defined herein to a person in need thereof. The person in need thereof may be a person having a neuromuscular disorder or a person at risk of developing a neuromuscular disorder or a person having symptoms of muscle weakness and / or fatigue. In another embodiment the person in need thereof is a person with reduced neuromuscular transmission safety with prolonged recovery P7162PC00 88 after neuromuscular blockade. Types of neuromuscular disorders are defined herein above. In an embodiment the person has amyotrophic lateral sclerosis, spinal muscular atrophy, myasthenia gravis or Lambert–Eaton syndrome. A therapeutically effective amount is an amount that produces a therapeutic response or desired effect in the person taking it. Administration routes, formulations and dosages can be optimized by persons of skill in the art. The method of treatment may be combined with other methods that are known to treat, prevent and / or ameliorate neuromuscular disorders. The treatment method may for example be combined with administration of any of the agents mentioned herein above. In one embodiment the treatment is combined with administration of acetylcholine esterase inhibitor such as for example neostigmine or pyridostigmine. In one aspect, the invention relates to a method for recovery of force in muscles with neuromuscular dysfunction, said method comprising administering a compound or a composition as defined herein to a subject in need thereof. The term “recovery of force in muscles with neuromuscular dysfunction” as used herein refers to the ability of a compound to recover contractile force in nerve-stimulated healthy rat muscle after exposure to submaximal concentration (115 nM) of tubocurarine for 90 minutes. Recovery of force is quantified as the percentage of the force prior to tubocurarine that is recovered after addition of the compound. In one embodiment, said recovery of force is >5%, such as >10%, such as >15%, such as >20%, such as >25%, such as >30%, such as >35%. In one aspect, the present invention relates to a method of treating botulism poisoning, snake bites or nerve gas poisoning or preventing nerve gas poisoning, said method comprising administering a therapeutically effective amount of the compound as defined herein to a person in need thereof. Another aspect of the disclosure relates to use of a compound as defined herein, for the manufacture of a medicament for the treatment, prevention and / or amelioration of a neuromuscular disorder. P7162PC00 89 Another aspect relates to use of a compound as defined herein, for the manufacture of a medicament or a reversal agent for reversing and / or ameliorating a neuromuscular blockade after surgery. In one aspect, the present invention related to use of a compound as defined herein for the manufacture of a medicament for the treatment of botulism poisoning, snake bites or nerve gas poisoning or prevention of nerve gas poisoning. Method of manufacturing In one aspect, the present disclosure relates to methods of manufacturing compounds or compounds for use according to formula (I). Compounds according to the present invention may be prepared according to any conventional methods of chemical synthesis known by the skilled person, e.g. those described in the working examples. The starting materials for the processes described in the present application are known or may readily be prepared by conventional methods known by the skilled artisan from commercially available chemicals. The end products of the reactions described herein may be isolated by conventional technique such as extraction, crystallisation, distillation, chromatography etc. The compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention. Items1. A compound of Formula (I): P7162PC00 90 Formula (I) wherein:- M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;wherein R5 and R6, or R5 and R9, or R5 and R10, or R5 and R12, or R6 and R9, or R6and R10, or R6 and R12, or R7 and R8, or R9 and R10, or R9 and R11, or R10and R11, or R11 and R12, are optionally joined together to form a ringtogether with the intervening atom(s);- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C2-3alkenyl optionally substituted with one or more, identical or different, substituents R13; -OC1-3 alkyl optionally substituted with one or more, identical or different, substituents R14; -OC3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R14; - SC1-3 alkyl optionally substituted with one or more, identical or different, substituents R14and -SC3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R14; and- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3 cycloalkyl optionally substituted with one or more, identical or different, substituents R14; or R1is linked to R2to form a ring together with the intervening atoms, and R1is C1-3 alkanediyl optionally substituted with one or more, identical ordifferent, substituents R13, or -O-C1-3 alkanediyl optionally substitutedwith one or more, identical or different, substituents R13, and R2is C1-3 alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of: P7162PC00 91 , -R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,or when R5 is linked to R6, R9, R10 or R12 to form a ring, then R5 is C1-3 alkanediyloptionally substituted with one or more, identical or different, substituents R13; -R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R6 is linked to R5, R9, R10 or R12 to form a ring, then R6 is C1-3 alkanediyloptionally substituted with one or more, identical or different, substituents R13; -R7 is independently selected from the group consisting of H, deuterium, F and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, or when R7 is linked to R8 to form a ring, then R7 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13; -R8 is independently selected from the group consisting of H, deuterium, F, and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, or when R8 is linked to R7 to form a ring, then R8 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13; -R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, P7162PC00 92 or when R9 is linked to R5, R6, R10 or R11 to form a ring, then R9 is C1-3 alkanediyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R10 is linked to R5, R6, R9 or R11, then R10 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substituted withone or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,or when R11 is linked to R9, R10, or R12, then R11 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substituted withone or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R12 is linked to R5, R6, or R11, then R12 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R13 is independently selected from the group consisting of deuterium, F, Cl, CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium, F, Cl, andCN;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, -OR18, - SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or more F, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, P7162PC00 93 identical or different, substituents R17, 5- to 10-membered heterocycleoptionally substituted with one or more, identical or different, substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8bicycloalkyl; -R17 is independently selected from the group consisting of deuterium, methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl, CN,C1-3 alkyl optionally substituted with one or more F, and C3-5 cycloalkyl;- R19 is independently selected from the group consisting of deuterium, methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and=O; and- R20 is independently selected from the group consisting of H, deuterium and F;or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.2. A compound of Formula (I): Formula (I) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;wherein R5 and R6, or R5 and R9, or R5 and R10, or R5 and R12, or R6 and R9, or R6and R10, or R6 and R12, or R7 and R8, or R9 and R10, or R9 and R11, or R10 P7162PC00 94 and R11, or R11 and R12, are optionally joined together to form a ringtogether with the intervening atom(s); -R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C2-3alkenyl optionally substituted with one or more, identical or different, substituents R13; -OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -OC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; - SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14and -SC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; andR2is selected from the group consisting of F; Cl; Br; C1-3alkyl optionally substituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14; or R1is linked to R2to form a ring together with the intervening atoms, and R1is C1-3 alkanediyl optionally substituted with one or more, identical ordifferent, substituents R13, or -O-C1-3 alkanediyl optionally substitutedwith one or more, identical or different, substituents R13, and R2is C1-3 alkanediyl optionally substituted with one or more, identical or different,substituents R13; -R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:, -R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15, P7162PC00 95 or when R5 is linked to R6, R9, R10 or R12 to form a ring, then R5 is C1-3 alkanediyloptionally substituted with one or more, identical or different, substituents R13;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R6 is linked to R5, R9, R10 or R12 to form a ring, then R6 is C1-3 alkanediyloptionally substituted with one or more, identical or different, substituents R13;- R7 is independently selected from the group consisting of H, deuterium, F and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, or when R7 is linked to R8 to form a ring, then R7 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F, and C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13, or when R8 is linked to R7 to form a ring, then R8 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R9 is linked to R5, R6, R10 or R11 to form a ring, then R9 is C1-3 alkanediyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R10 is linked to R5, R6, R9 or R11, then R10 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substituted withone or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15, P7162PC00 96 or when R11 is linked to R9, R10, or R12, then R11 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substituted withone or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R12 is linked to R5, R6, or R11, then R12 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R13 is independently selected from the group consisting of deuterium, F, Cl, CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium, F, Cl, andCN;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, -OR18, - SR18, -OCH2R18, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-membered heterocycle optionally substituted with one or more, identicalor different, substituents R19, 5- to 10-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17, and C5-8 bicycloalkyl;- R17 is independently selected from the group consisting of deuterium, methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F;- R18 is independently selected from the group consisting of deuterium, F, Cl, CN,C1-3 alkyl, and C3-5 cycloalkyl;- R19 is independently selected from the group consisting of deuterium, methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and=O; and P7162PC00 97 -R20 is independently selected from the group consisting of H, deuterium and F;or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.3. A compound of Formula (I): Formula (I) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;wherein R5 and R6, or R5 and R9, or R5 and R10, or R5 and R12, or R6 and R9, orR6 and R10, or R6 and R12, or R7 and R8, or R9 and R10, or R9 and R11, orR10 and R11, or R11 and R12, are optionally joined together to form a ringtogether with the intervening atom(s); -R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C2-3alkenyl optionally substituted with one or more, identical or different, substituents R13; -OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -OC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; - SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14and -SC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; andR2is selected from the group consisting of F; Cl; Br; C1-3alkyl optionally substituted with one or more, identical or different, substituents R14and C3 cycloalkyl optionally substituted with one or more, identical or different, substituents R14; P7162PC00 98 or R1is linked to R2to form a ring together with the intervening atoms, and R1 is C1-3 alkanediyl optionally substituted with one or more, identical ordifferent, substituents R13, or -O-C1-3 alkanediyl optionally substitutedwith one or more, identical or different, substituents R13, and R2is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:, - R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,or when R5 is linked to R6, R9, R10 or R12 to form a ring, then R5 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R6 is linked to R5, R9, R10 or R12 to form a ring, then R6 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, or when R7 is linked to R8 to form a ring, then R7 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13; P7162PC00 99- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, or when R8 is linked to R7 to form a ring, then R8 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R9 is linked to R5, R6, R10 or R11 to form a ring, then R9 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R10is linked to R5, R6, R9or R11, then R10is C1-3 alkanediyl optionally substituted with one or more, identical or different, substituents R13;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,or when R11 is linked to R9, R10, or R12, then R11 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R12 is linked to R5, R6, or R11, then R12 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium, F, Cl,and CN; P7162PC00 100 -R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17; -R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8bicycloalkyl; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; -R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano,Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof; with the proviso that the compound is not selected from the group consisting of 5-(6-fluoro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4-oxazolidinedione and 5-(6-chloro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4- oxazolidinedione.4. A compound of Formula (I): P7162PC00 101 Formula (I) wherein:- M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C2-3alkenyl optionally substituted with one or more, identical or different, substituents R13; -OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -OC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; - SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14and -SC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; and- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14;- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:, P7162PC00 102- R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13,- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13,- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13,- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13,- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium, F, Cl,and CN;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical P7162PC00 103 or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17; -R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8bicycloalkyl; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; -R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.5. A compound of Formula (I): Formula (I) P7162PC00 104 wherein:- M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C2-3alkenyl optionally substituted with one or more, identical or different, substituents R13; -OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -OC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; - SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14and -SC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; and- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3 cycloalkyl optionally substituted with one or more, identical or different, substituents R14;- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of: ;- R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13,- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13, P7162PC00 105- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13,- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13,- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium, F, Cl,and CN;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, 5- to 10-membered heteroaryl optionally substituted P7162PC00 106 with one or more, identical or different, substituents R17, and C5-8bicycloalkyl; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; -R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.6. A compound of Formula (I): Formula (I) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; and P7162PC00 107 -OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14;- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14;- R3 is H or F;- R4 is selected from the group consisting of:, - R5 is selected from the group consisting of H; deuterium; F; and C1-3 alkyl;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyl;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyl;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyl;- R11 is H or C1-3 alkyl optionally substituted with one or more, identical ordifferent, substituents R13;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R16 is independently selected from the group consisting of -OR18, -OCH2R18,C1-3 alkyl optionally substituted with one or more F, -C3-5 cycloalkyl P7162PC00 108 optionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17, and 5- to 6-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; -R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, Cl, Br, and F; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.7. The compound according to any one of the preceding items, wherein thecompound is of formula (VIII): . Formula (VIII)8. The compound according to any one of the preceding items, wherein thecompound is of formula (IX): . P7162PC00 109 Formula (IX)9. The compound according to any one of the preceding items, wherein thecompound is of formula (X): . Formula (X)10. The compound according to any one of the preceding items, wherein thecompound is of formula (XI): . Formula (XI)11. The compound according to any one of the preceding items, wherein thecompound is of formula (XII): . Formula (XII)12. The compound according to any one of the preceding items, wherein thecompound is of formula (III) or formula (IV): P7162PC00 110 . Formula (III) Formula (IV)13. The compound according to any one of the preceding items, wherein compoundis of formula (II): Formula (II) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; and -SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14; -R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of: P7162PC00 111 , -R5 selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; -R7 is independently selected from the group consisting of H, deuterium, Fand C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13; -R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13; -R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; -R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyl P7162PC00 112 optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8 bicycloalkyl;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F;- R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl;- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. P7162PC00 11314. The compound according any one of the preceding items, wherein compound isof formula (III): Formula (III) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - OC1-3 alkyl optionally substituted with one or more, identical or different, substituents R14; and -SC1-3 alkyl optionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3 cycloalkyl optionally substituted with one or more, identical or different, substituents R14; -R3 is selected from the group consisting of H; F and Cl;- R5 selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; P7162PC00 114- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-membered P7162PC00 115 heterocycle optionally substituted with one or more, identical or different,substituents R19, and 5- to 10-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; and- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O;or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.15. The compound according to any one of the preceding items, wherein compoundis of formula (IV): Formula (IV) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - P7162PC00 116 OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; and -SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14;- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14;- R3 is selected from the group consisting of H; F and Cl;- R5 selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyl P7162PC00 117 optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, and 5- to 10-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F;- R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl;- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. P7162PC00 11816. The compound according to any one of the preceding items, wherein compoundis of formula (V): Formula (V) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; and -SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14; -R3 is selected from the group consisting of H; F and Cl;- R5 selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; P7162PC00 119- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-membered P7162PC00 120 heterocycle optionally substituted with one or more, identical or different,substituents R19, and 5- to 10-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; -R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.17. The compound according to any one of the preceding items, wherein compoundis of formula (VI): Formula (VI) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S; P7162PC00 121- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; and -SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14;- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14;- R3 is selected from the group consisting of H; F and Cl;- R5 selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15; P7162PC00 122- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19 and 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F;- R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; and- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O;or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof. P7162PC00 12318. The compound according to any one of the preceding items, wherein compoundis of formula (VII): Formula (VII) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; and -SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14; -R3 is selected from the group consisting of H; F and Cl;- R5 selected from the group consisting of H; deuterium; F; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; P7162PC00 124- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-membered P7162PC00 125 heterocycle optionally substituted with one or more, identical or different,substituents R19 and 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; and- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; andor a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.19. The compound according to any one of the preceding items, wherein compoundis of formula (II): Formula (II) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; and-OC1-3 alkyl optionally substituted with one or more, identical or different, substituents R14; P7162PC00 126- R2 is selected from the group consisting of F; Cl; Br; and C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14;- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:, - R5 selected from the group consisting of H; deuterium; F; and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is H or C1-3 alkyl optionally substituted with one or more, identical ordifferent, substituents R13;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyl P7162PC00 127 optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, andCl; -R14 is independently selected from the group consisting of deuterium, F, Cl,and CN; -R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8 bicycloalkyl; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; -R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O, and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.20. The compound according to any one of the preceding items, wherein compoundis of formula (II): P7162PC00 128 Formula (II) wherein:- M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; and -OC1-3 alkyloptionally substituted with one or more, identical or different, substituents R14;- R2 is selected from the group consisting of F; Cl; and Br;- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:, - R5 selected from the group consisting of H; deuterium; F; and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13; P7162PC00 129- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is H or C1-3 alkyl optionally substituted with one or more, identical ordifferent, substituents R13;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, andCl;- R14 is independently selected from the group consisting of deuterium, F, Cl,and CN;- R16 is independently selected from the group consisting of -C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, C1-3 alkyl optionally substituted with one or more F, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-membered heterocycle optionally substitutedwith one or more, identical or different, substituents R19 and 5- to 10-membered heteroaryl optionally substituted with one or more, identicalor different, substituents R17;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, cyano, Cl, Br, and F;- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, cyano, Cl, Br, and F; and P7162PC00 130 -R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.21. The compound according to item 1, wherein compound is of formula (III) orformula (IV): Formula (III) Formula (IV) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; and -OC1-3 alkyloptionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; Br; and C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14; -R3 is H;- R5 is selected from the group consisting of H; deuterium and F;- R6 is selected from the group consisting of H, deuterium and F;- R7 is independently selected from the group consisting of H, deuterium, andMe; -R8 is independently selected from the group consisting of H, deuterium andMe; P7162PC00 131- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H and Me;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R16 is independently selected from the group consisting of -OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or more F, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6 aryl optionally substituted with one or more, identical or different, substituents R17 and 5-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F;- R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl;- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; P7162PC00 132 or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.22. The compound according to any one of the preceding items, wherein X is absent.23. The compound according to any one of the preceding items, wherein X is CR7R8.24. The compound according to any one of the preceding items, wherein M is CR5R6.25. The compound according to any one of the preceding items, wherein M is NR11.26. The compound according to any one of the preceding items, wherein M is O.27. The compound according to any one of the preceding items, wherein M is S.28. The compound according to any one of the preceding items, wherein Z isCR10R9.29. The compound according to any one of the preceding items, wherein Z is NR12.30. The compound according to any one of the preceding items, wherein Z is O.31. The compound according to any one of the preceding items, wherein Z is S.32. The compound according to any one of the preceding items, wherein M is CR5R6and Z is CR9R10.33. The compound according to any one of the preceding items, wherein M is CR5R6and Z is NR12.34. The compound according to any one of the preceding items, wherein M is CR5R6and Z is O.35. The compound according to any one of the preceding items, wherein M is CR5R6and Z is S.36. The compound according to any one of the preceding items, wherein M is NR11and Z is O.37. The compound according to any one of the preceding items, wherein M is NR11and Z is S. P7162PC00 13338. The compound according to any one of the preceding items, wherein M is NR11and Z is CR9R10.39. The compound according to any one of the preceding items, wherein M is O andZ is NR12.40. The compound according to any one of the preceding items, wherein M is O andZ is CR10R9.41. The compound according to any one of the preceding items, wherein M is S andZ is CR9R10.42. The compound according to any one of the preceding items, wherein M is O andZ is O.43. The compound according to any one of the preceding items, wherein M is S andZ is O.44. The compound according to any one of the proceeding items, wherein M is O, Qis CH2, T is CH2, X is absent, and Z is NR12.45. The compound according to any one of the preceding items, wherein M is O, Q isC(CH3)2, T CH2, is X is absent, and Z is NR12.46. The compound according to any one of the preceding items, wherein M is O, Q isCH2, T is C(CH3)2, X is absent, and Z is NR12.47. The compound according to any one of the preceding items, wherein M is CH2, Qis CH2, T is CH2, X is absent, and Z is NR12.48. The compound according to any one of the preceding items, wherein M is NR11,Q is CH2, T is CH2, X is absent, and Z is O.49. The compound according to any one of the preceding items, wherein R1 isselected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13; and -OC1-3 alkyloptionally substituted with one or more, identical or different, substituents R14. P7162PC00 13450. The compound according to any one of the preceding items, wherein R1 isselected from the group consisting of H; F; Cl; Br; and -OC1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14.51. The compound according to any one of the preceding items, wherein R1 is H.52. The compound according to any one of the preceding items, wherein R1 is F.53. The compound according to any one of the preceding items, wherein R1 is Cl.54. The compound according to any one of the preceding items, wherein R1 is Br.55. The compound according to any one of the preceding items, wherein R1 is C1-3alkyl substituted with one or more, identical or different, substituents R13.56. The compound according to any one of the preceding items, wherein R1 is C1-3alkyl.57. The compound according to any one of the preceding items, wherein R1 is C2-3alkenyl substituted with one or more, identical or different, substituents R13.58. The compound according to any one of the preceding items, wherein R1 is C2-3alkenyl59. The compound according to any one of the preceding items, wherein R1 is -OC1-3alkyl.60. The compound according to any one of the preceding items, wherein R1 is -OCH3.61. The compound according to any one of the preceding items, wherein R1 is -OCH2CH3.62. The compound according to any one of the preceding items, wherein R1 is -OC1-3alkyl substituted with one or more, identical or different, substituents R14.63. The compound according to any one of the preceding items, wherein R1 is-OC3-5cycloalkyl. P7162PC00 13564. The compound according to any one of the preceding items, wherein R1 is-OC3-5cycloalkyl substituted with one or more, identical or different, substituents R14.65. The compound according to any one of the preceding items, wherein R1 is -SC1-3alkyl.66. The compound according to any one of the preceding items, wherein R1 is -SC1-3alkyl substituted with one or more, identical or different, substituents R14.67. The compound according to any one of the preceding items, wherein R1 is SC3-5cycloalkyl.68. The compound according to any one of the preceding items, wherein R1 is SC3-5cycloalkyl substituted with one or more, identical or different, substituents R14.69. The compound according to any one of the preceding items, wherein R1 isselected from the group consisting of H; F; Cl; Br; CH3; -OCH3; and -O CH2CH3.70. The compound according to any one of the preceding items, wherein R2 isselected from the group consisting of F; Cl; Br; and C1-3alkyl optionally substituted with one or more, identical or different, substituents R14.71. The compound according to any one of the preceding items, wherein R2 is F.72. The compound according to any one of the preceding items, wherein R2 is Cl.73. The compound according to any one of the preceding items, wherein R2 is Br.74. The compound according to any one of the preceding items, wherein R2 is C1-3alkyl.75. The compound according to any one of the preceding items, wherein R2 is C1-3alkyl substituted with one or more, identical or different, substituents R14.76. The compound according to any one of the preceding items, wherein R2 is CH3.77. The compound according to any one of the preceding items, wherein R2 is C3cycloalkyl. P7162PC00 13678. The compound according to any one of the preceding items, wherein R2 is C3cycloalkyl substituted with one or more, identical or different, substituents R14.79. The compound according to any one of the preceding items, wherein R2 isselected from the group consisting of F; Cl; Br; C1-3alkyl, and C3cycloalkyl.80. The compound according to any one of the preceding items, wherein R1 is linkedto R2to form a ring together with the intervening atoms.81. The compound according to any one of the preceding items, wherein R1 is C1-3alkanediyl.82. The compound according to any one of the preceding items, wherein R1 is C1-3alkanediyl substituted with one or more, identical or different, substituents R13.83. The compound according to any one of the preceding items, wherein R1 is -O-C1-3alkanediyl.84. The compound according to any one of the preceding items, wherein R1 is -O-C1-3 alkanediyl substituted with one or more, identical or different, substituents R13.85. The compound according to any one of the preceding items, wherein R2 is C1-3alkanediyl.86. The compound according to any one of the preceding items, wherein R2 is C1-3alkanediyl substituted with one or more, identical or different, substituents R13.87. The compound according to any one of the preceding items, wherein R3 is H.88. The compound according to any one of the preceding items, wherein R3 is F.89. The compound according to any one of the preceding items, wherein R3 is Cl.90. The compound according to any one of the preceding items, wherein- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; and -OC1-3 alkyl optionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and P7162PC00 137 C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14; -R3 is H or F;- R13 is independently selected from the group consisting of deuterium and F;and -R14 is independently selected from the group consisting of deuterium and F.91. The compound according to any one of the preceding items, wherein R1 isselected from the group consisting of H; F; Cl; Br; CH3; -OCH3; and -OCH2CH3;R2is selected from the group consisting of F; Cl; Br; C1-3alkyl, and C3cycloalkyl; and R3 is H.92. The compound according to any one of the preceding items, wherein- R1 is selected from the group consisting of H; F; Cl; Br; and -OC1-3 alkyloptionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; Br; and C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14; -R3 is H; and- R14 is independently selected from the group consisting of deuterium and F.93. The compound according to any one of the preceding items, wherein R4 is .94. The compound according to any one of the preceding items, wherein R4 is95. to any one of the preceding items, wherein R4 is . P7162PC00 13896. The compound according to any one of the preceding items, wherein R4 is .97. The compound according to any one of the preceding items, wherein R4 is .98. The compound according to any one of the preceding items, wherein R4 is .99. The compound according to any one of the preceding items, wherein R4 is .100. The compound according to any one of the preceding items, wherein R4 is .101. The compound according to any one of the preceding items, wherein R4 is . P7162PC00 139102. The compound according to any one of the preceding items, wherein R4 is.103. The compound according to any one of the preceding items, wherein R20 is H.104. The compound according to any one of the preceding items, wherein R20 isdeuterium.105. The compound according to any one of the preceding items, wherein R20 is F.106. The compound according to any one of the preceding items, wherein R5 is H.107. The compound according to any one of the preceding items, wherein R5 selectedfrom the group consisting of H; deuterium; F; and C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13.108. The compound according to any one of the preceding items, wherein R5 isdeuterium.109. The compound according to any one of the preceding items, wherein R5 is F.110. The compound according to any one of the preceding items, wherein R5 is C1-3alkyl.111. The compound according to any one of the preceding items, wherein R5 is C1-5alkyl substituted with one or more, identical or different, substituents R13.112. The compound according to any one of the preceding items, wherein R5 is C1-3alkyl substituted with one or more, identical or different, substituents R13.113. The compound according to any one of the preceding items, wherein R5 selectedfrom the group consisting of H; deuterium; and F.114. The compound according to any one of the preceding items, wherein R5 is C3-5cycloalkyl. P7162PC00 140115. The compound according to any one of the preceding items, wherein R5 is C3-5cycloalkyl substituted with one or more, identical or different, substituents R13.116. The compound according to any one of the preceding items, wherein R5 is C1-3alkyl substituted with R15.117. The compound according to any one of the preceding items, wherein R6 is H.118. The compound according to any one of the preceding items, wherein R6 isdeuterium.119. The compound according to any one of the preceding items, wherein R6 is F.120. The compound according to any one of the preceding items, wherein R6 selectedfrom the group consisting of H; deuterium; and F.121. The compound according to any one of the preceding items, wherein R6 is C1-3alkyl.122. The compound according to any one of the preceding items, wherein R6 is CH3.123. The compound according to any one of the preceding items, wherein R6 is C1-3alkyl substituted with one or more, identical or different, substituents R13.124. The compound according to any one of the preceding items, wherein R7 is H.125. The compound according to any one of the preceding items, wherein R7 isdeuterium.126. The compound according to any one of the preceding items, wherein R7 is F.127. The compound according to any one of the preceding items, wherein R7 is C1-3alkyl.128. The compound according to any one of the preceding items, wherein R7 is CH3.129. The compound according to any one of the preceding items, wherein R7 is C1-3alkyl substituted with one or more, identical or different, substituents R13.130. The compound according to any one of the preceding items, wherein R7 isselected from the group consisting of H; deuterium; F; and Me. P7162PC00 141131. The compound according to any one of the preceding items, wherein R8 is H.132. The compound according to any one of the preceding items, wherein R8 isdeuterium.133. The compound according to any one of the preceding items, wherein R8 is F.134. The compound according to any one of the preceding items, wherein R8 is C1-3alkyl.135. The compound according to any one of the preceding items, wherein R8 is CH3.136. The compound according to any one of the preceding items, wherein R8 is C1-3alkyl substituted with one or more, identical or different, substituents R13.137. The compound according to any one of the preceding items, wherein R8 isselected from the group consisting of H; deuterium; F; and Me.138. The compound according to any one of the preceding items, wherein R9 is H.139. The compound according to any one of the preceding items, wherein R9 isdeuterium.140. The compound according to any one of the preceding items, wherein R9 is F.141. The compound according to any one of the preceding items, wherein R9 is C1-3alkyl.142. The compound according to any one of the preceding items, wherein R9 is CH3.143. The compound according to any one of the preceding items, wherein R9 is C1-3alkyl substituted with one or more, identical or different, substituents R13.144. The compound according to any one of the preceding items, wherein R9 isselected from the group consisting of H, deuterium, F, and C1-3 alkyl.145. The compound according to any one of the preceding items, wherein R10 is H.146. The compound according to any one of the preceding items, wherein R10 isdeuterium. P7162PC00 142147. The compound according to any one of the preceding items, wherein R10 is F.148. The compound according to any one of the preceding items, wherein R10 is C1-3alkyl.149. The compound according to any one of the preceding items, wherein R10 is C1-3alkyl substituted with one or more, identical or different, substituents R13.150. The compound according to any one of the preceding items, wherein R10 is C3-5cycloalkyl.151. The compound according to any one of the preceding items, wherein R10 is C3-5cycloalkyl substituted with one or more, identical or different, substituents R13.152. The compound according to any one of the preceding items, wherein R10 is C1-3alkyl substituted with R16.153. The compound according to any one of the preceding items, wherein R10 isselected from the group consisting of H, deuterium, F, and C1-3alkyl.154. The compound according to any one of the preceding items, wherein R11 is H orC1-3 alkyl optionally substituted with one or more, identical or different, substituents R13.155. The compound according to any one of the preceding items, wherein R11 is H.156. The compound according to any one of the preceding items, wherein R11 is C1-3alkyl.157. The compound according to any one of the preceding items, wherein R11 is CH3.158. The compound according to any one of the preceding items, wherein R11 is C1-3alkyl substituted with one or more, identical or different, substituents R13.159. The compound according to any one of the preceding items, wherein R11 is H orMe.160. The compound according to any one of the preceding items, wherein R11 is C3-5cycloalkyl. P7162PC00 143161. The compound according to any one of the preceding items, wherein R11 is C3-5cycloalkyl substituted with one or more, identical or different, substituents R13.162. The compound according to any one of the preceding items, wherein R11 is C1-3alkyl substituted with R15.163. The compound according to any one of the preceding items, wherein R12 is H.164. The compound according to any one of the preceding items, wherein R12 is C1-3alkyl.165. The compound according to any one of the preceding items, wherein R12 ismethyl.166. The compound according to any one of the preceding items, wherein R12 is ethyl.167. The compound according to any one of the preceding items, wherein R12 ispropyl, such as n-propyl or isopropyl.168. The compound according to any one of the preceding items, wherein R12 is butyl,such as isobutyl.169. The compound according to any one of the preceding items, wherein R12 ispentyl, such as isopentyl.170. The compound according to any one of the preceding items, wherein R12 is C1-3alkyl substituted with one or more, identical or different, substituents R13.171. The compound according to any one of the preceding items, wherein R12 is C1-3alkyl substituted with one or more, identical or different, substituents R13wherein R13is -OC1-3 alkyl.172. The compound according to any one of the preceding items, wherein R12 is C2alkyl substituted with -OC1-3 alkyl.173. The compound according to any one of the preceding items, wherein R12 is -(CH2)2OCH3, -(CH2)2OCH2CH3, -(CH2)2OCH(CH3)2. P7162PC00 144174. The compound according to any one of the preceding items, wherein R12 is C1-3alkyl substituted with one or more, identical or different, substituents R13wherein R13is -OC3-5cycloalkyl.175. The compound according to any one of the preceding items, wherein R12 is .176. The compound according to any one of the preceding items, wherein R12 is C1-3alkyl substituted with one or more F.177. The compound according to any one of the preceding items, wherein R12 is -CH2CH2F, -CH2CHF2.178. The compound according to any one of the preceding items, wherein R12 is C3-5cycloalkyl.179. The compound according to any one of the preceding items, wherein R12 is C3-5cycloalkyl substituted with one or more, identical or different, substituents R13.180. The compound according to any one of the preceding items, wherein R12 is C1-3alkyl substituted with R16.181. The compound according to any one of the preceding items, wherein R12 is C1alkyl substituted with R16.182. The compound according to any one of the preceding items, wherein R5 is linkedto R6to form a ring together with the intervening atom.183. The compound according to any one of the preceding items, wherein R5 is linkedto R9to form a ring together with the intervening atoms.184. The compound according to any one of the preceding items, wherein R5 is linkedto R10to form a ring together with the intervening atoms.185. The compound according to any one of the preceding items, wherein R5 is linkedto R12to form a ring together with the intervening atoms.186. The compound according to any one of the preceding items, wherein R6 is linkedto R9to form a ring together with the intervening atoms. P7162PC00 145187. The compound according to any one of the preceding items, wherein R6 is linkedto R10to form a ring together with the intervening atoms.188. The compound according to any one of the preceding items, wherein R6 is linkedto R12to form a ring together with the intervening atoms.189. The compound according to any one of the preceding items, wherein R7 is linkedto R8to form a ring together with the intervening atom(s).190. The compound according to any one of the preceding items, wherein R9 is linkedto R10to form a ring together with the intervening atoms.191. The compound according to any one of the preceding items, wherein R9 is linkedto R11to form a ring together with the intervening atoms.192. The compound according to any one of the preceding items, wherein R10 is linkedto R11to form a ring together with the intervening atom.193. The compound according to any one of the preceding items, wherein R11 is linkedto R12to form a ring together with the intervening atoms.194. The compound according to any one of the preceding items, wherein R5 is C1-3alkanediyl.195. The compound according to any one of the preceding items, wherein R5 is C1-3alkanediyl substituted with one or more, identical or different, substituents R13.196. The compound according to any one of the preceding items, wherein R6 is C1-3alkanediyl.197. The compound according to any one of the preceding items, wherein R6 is C1-3alkanediyl substituted with one or more, identical or different, substituents R13.198. The compound according to any one of the preceding items, wherein R7 is C1-3alkanediyl.199. The compound according to any one of the preceding items, wherein R7 is C1-3alkanediyl substituted with one or more, identical or different, substituents R13. P7162PC00 146200. The compound according to any one of the preceding items, wherein R8 is C1-3alkanediyl.201. The compound according to any one of the preceding items, wherein R8 is C1-3alkanediyl substituted with one or more, identical or different, substituents R13.202. The compound according to any one of the preceding items, wherein R9 is C1-3alkanediyl.203. The compound according to any one of the preceding items, wherein R9 is C1-3alkanediyl substituted with one or more, identical or different, substituents R13.204. The compound according to any one of the preceding items, wherein R10 is C1-3alkanediyl.205. The compound according to any one of the preceding items, wherein R10 is C1-3alkanediyl substituted with one or more, identical or different, substituents R13.206. The compound according to any one of the preceding items, wherein R11 is C1-3alkanediyl.207. The compound according to any one of the preceding items, wherein R11 is C1-3alkanediyl substituted with one or more, identical or different, substituents R13.208. The compound according to any one of the preceding items, wherein R12 is C1-3alkanediyl.209. The compound according to any one of the preceding items, wherein R12 is C1-3alkanediyl substituted with one or more, identical or different, substituents R13.210. The compound according to any one of the preceding items, wherein R13 isdeuterium.211. The compound according to any one of the preceding items, wherein R13 is F.212. The compound according to any one of the preceding items, wherein R13 is Cl.213. The compound according to any one of the preceding items, wherein R13 is CN. P7162PC00 147214. The compound according to any one of the preceding items, wherein R13 is -OC1-3alkyl.215. The compound according to any one of the preceding items, wherein R13 is -OCH3.216. The compound according to any one of the preceding items, wherein R13 is -OC3-5cycloalkyl.217. The compound according to any one of the preceding items, wherein R14 isindependently selected from the group consisting of deuterium, F, and Cl.218. The compound according to any one of the preceding items, wherein R14 isdeuterium.219. The compound according to any one of the preceding items, wherein R14 is F.220. The compound according to any one of the preceding items, wherein R14 isdeuterium or F.221. The compound according to any one of the preceding items, wherein R14 is Cl.222. The compound according to any one of the preceding items, wherein R14 is CN.223. The compound according to any one of the preceding items, wherein R15 is C3-5cycloalkyl.224. The compound according to any one of the preceding items, wherein R15 is C3-5cycloalkyl substituted with one or more, identical or different, substituents R13.225. The compound according to any one of the preceding items, wherein R15 isphenyl.226. The compound according to any one of the preceding items, wherein R15 isphenyl substituted with one or more, identical or different, substituents R17.227. The compound according to any one of the preceding items, wherein R15 is a 5-membered heteroaryl. P7162PC00 148228. The compound according to any one of the preceding items, wherein R15 is a 5-membered heteroaryl substituted with one or more, identical or different, substituents R17.229. The compound according to any one of the preceding items, wherein R16 isindependently selected from the group consisting of -C3-5 cycloalkyl optionallysubstituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-membered heterocycle optionally substituted with one or more, identical ordifferent, substituents R19, and 5- to 10-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17.230. The compound according to any one of the preceding items, wherein R16 isindependently selected from the group consisting of -C3-5 cycloalkyl optionallysubstituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-membered heterocycle optionally substituted with one or more, identical ordifferent, substituents R19, and 5- to 10-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17.231. The compound according to any one of the preceding items, wherein R16 isindependently selected from the group consisting of -OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or more F, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17, and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17.232. The compound according to any one of the preceding items, wherein R16 isindependently selected from the group consisting of -OR18, -OCH2R18, C1-3 alkyl optionally substituted with one or more F, -C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17, and 5- to 6-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17. P7162PC00 149233. The compound according to any one of the preceding items, wherein R16 is -C(=O)N(R18)2.234. The compound according to any one of the preceding items, wherein R16 is -NR18-C(=O)-R18.235. The compound according to any one of the preceding items, wherein R16 is -NR18-SO2-R18.236. The compound according to any one of the preceding items, wherein R16 is -SO2-N(R18)2.237. The compound according to any one of the preceding items, wherein R16 is -SO2-R18.238. The compound according to any one of the preceding items, wherein R16 is -C(=O)-R18.239. The compound according to any one of the preceding items, wherein R16 is -OR18.240. The compound according to any one of the preceding items, wherein R16 is -SR18.241. The compound according to any one of the preceding items, wherein R16 is -OCH2R18.242. The compound according to any one of the preceding items, wherein R16 is -C3-5cycloalkyl.243. The compound according to any one of the preceding items, wherein R16 iscyclobutyl.244. The compound according to any one of the preceding items, wherein R16 iscyclopropyl.245. The compound according to any one of the preceding items, wherein R16 is C1-3alkyl optionally substituted with one or more F. P7162PC00 150246. The compound according to any one of the preceding items, wherein R16 is -CF3,-CHF2, or -CH2F.247. The compound according to any one of the preceding items, wherein R12 is -(CH2)3CH2F or -(CH2)3CF3.248. The compound according to any one of the preceding items, wherein R16 is -C3-5cycloalkyl substituted with one or more, identical or different, substituents R13.249. The compound according to any one of the preceding items, wherein R16 iscyclopropyl optionally substituted with one or more F.250. The compound according to any one of the preceding items, wherein R16 iscyclobutyl optionally substituted with one or more F.251. The compound according to any one of the preceding items, wherein R12 is .252. The compound according to any one of the preceding items, wherein R16 is C6-10aryl.253. The compound according to any one of the preceding items, wherein R16 isphenyl.254. The compound according to any one of the preceding items, wherein R16 is C6-10aryl substituted with one or more, identical or different, substituents R17.255. The compound according to any one of the preceding items, wherein the C6-10aryl is phenyl.256. The compound according to any one of the preceding items, wherein R16 isphenyl substituted with one or more, identical or different, substituents R17.257. The compound according to any one of the preceding items, wherein R16 isphenyl substituted with one or more, identical or different, substituents selectedfrom the group consisting of methoxy, methyl and F. P7162PC00 151258. The compound according to any one of the preceding items, wherein R16 is a 5-to 10-membered heterocycle.259. The compound according to any one of the preceding items, wherein R16 is a 5-to 10-membered heterocycle substituted with one or more, identical or different,substituents R19.260. The compound according to any one of the preceding items, wherein R16 is a 5-to 10-membered heteroaryl.261. The compound according to any one of the preceding items, wherein R16 is a 5-to 10-membered heteroaryl substituted with one or more, identical or different,substituents R17.262. The compound according to any one of the preceding items, wherein R16 is a 5-to 10-membered heteroaryl and the 5- to 10-membered heteroaryl is a 6-membered heteroaryl.263. The compound according to any one of the preceding items, wherein R16 is a 5-to 10-membered heteroaryl and the 5- to 10-membered heteroaryl is a 5-membered heteroaryl.264. The compound according to any one of the preceding items, wherein R16 is a 5-to 10-membered heteroaryl and the 5- to 10-membered heteroaryl is selectedfrom the group consisting of thiophenyl, furanyl, oxazolyl, and isoxazolyl.265. The compound according to any one of the preceding items, wherein R16 isthiophenyl.266. The compound according to any one of the preceding items, wherein R16 isfuranyl.267. The compound according to any one of the preceding items, wherein R16 isoxazolyl.268. The compound according to any one of the preceding items, wherein R16 isisoxazolyl. P7162PC00 152269. The compound according to any one of the preceding items, wherein R16 is C5-8bicycloalkyl.270. The compound according to any one of the preceding items, wherein R16 isbicyclo[1.1.1]pentyl,271. The compound according to any one of the preceding items, wherein R17 isindependently selected from the group consisting of deuterium, methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, cyano, Cl, Br, and F.272. The compound according to any one of the preceding items, wherein R17 isdeuterium.273. The compound according to any one of the preceding items, wherein R17 ismethoxy.274. The compound according to any one of the preceding items, wherein R17 is -OCF3.275. The compound according to any one of the preceding items, wherein R17 isOCF2Cl.276. The compound according to any one of the preceding items, wherein R17 isOCF2H.277. The compound according to any one of the preceding items, wherein R17 isOCFH2.278. The compound according to any one of the preceding items, wherein R17 isOCD3.279. The compound according to any one of the preceding items, wherein R17 ismethyl.280. The compound according to any one of the preceding items, wherein R17 is CF3.281. The compound according to any one of the preceding items, wherein R17 isCF2Cl. P7162PC00 153282. The compound according to any one of the preceding items, wherein R17 isCF2H.283. The compound according to any one of the preceding items, wherein R17 isCFH2.284. The compound according to any one of the preceding items, wherein R17 is CD3.285. The compound according to any one of the preceding items, wherein R17 iscyclopropyl.286. The compound according to any one of the preceding items, wherein R17 is NH2.287. The compound according to any one of the preceding items, wherein R17is -NHAc.288. The compound according to any one of the preceding items, wherein R17 is -C(=O)-NH2.289. The compound according to any one of the preceding items, wherein R17 is nitro.290. The compound according to any one of the preceding items, wherein R17 is CN.291. The compound according to any one of the preceding items, wherein R17 is Cl.292. The compound according to any one of the preceding items, wherein R17 is Br.293. The compound according to any one of the preceding items, wherein R17 is F.294. The compound according to any one of the preceding items, wherein R18 isindependently selected from the group consisting of deuterium, F, Cl, CN, C1-3 alkyl, and C3-5 cycloalkyl.295. The compound according to any one of the preceding items, wherein R18 isdeuterium.296. The compound according to any one of the preceding items, wherein R18 is F.297. The compound according to any one of the preceding items, wherein R18 is Cl.298. The compound according to any one of the preceding items, wherein R18 is CN. P7162PC00 154299. The compound according to any one of the preceding items, wherein R18 is C1-3alkyl.300. The compound according to any one of the preceding items, wherein R18 is C1-3alkyl optionally substituted with one or more F.301. The compound according to any one of the preceding items, wherein R18 is C3-5cycloalkyl.302. The compound according to any one of the preceding items, wherein R19 isindependently selected from the group consisting of deuterium, methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, cyano, Cl, Br, and F.303. The compound according to any one of the preceding items, wherein R19 isdeuterium.304. The compound according to any one of the preceding items, wherein R19 ismethoxy.305. The compound according to any one of the preceding items, wherein R19 is -OCF3.306. The compound according to any one of the preceding items, wherein R19 isOCF2Cl.307. The compound according to any one of the preceding items, wherein R19 isOCF2H.308. The compound according to any one of the preceding items, wherein R19 isOCFH2.309. The compound according to any one of the preceding items, wherein R19 isOCD3.310. The compound according to any one of the preceding items, wherein R19 ismethyl.311. The compound according to any one of the preceding items, wherein R19 is CF3. P7162PC00 155312. The compound according to any one of the preceding items, wherein R19 isCF2Cl.313. The compound according to any one of the preceding items, wherein R19 isCF2H.314. The compound according to any one of the preceding items, wherein R19 isCFH2.315. The compound according to any one of the preceding items, wherein R19 is CD3.316. The compound according to any one of the preceding items, wherein R19 iscyclopropyl.317. The compound according to any one of the preceding items, wherein R19 is NH2.318. The compound according to any one of the preceding items, wherein R19is -NHAc.319. The compound according to any one of the preceding items, wherein R19 is -C(=O)-NH2.320. The compound according to any one of the preceding items, wherein R19 is nitro.321. The compound according to any one of the preceding items, wherein R19 is CN.322. The compound according to any one of the preceding items, wherein R19 is Cl.323. The compound according to any one of the preceding items, wherein R19 is Br.324. The compound according to any one of the preceding items, wherein R19 is F.325. The compound according to any one of the preceding items, wherein R19 is =O.326. The compound according to any one of the preceding items, wherein R12 isselected from the group consisting of: P7162PC00 156 , 328. The compound according to any one of the preceding items, wherein R12 isselected from the group consisting of: , 330. The compound according to any one of the preceding items, wherein R12 isselected from the group consisting of: .332. 333. The compound according to any one of the preceding items, wherein M is CH2.334. The compound according to any one of the preceding items, wherein M isN(CH3). 335. The compound according to any one of the preceding items, wherein Q is CH2.336. The compound according to any one of the preceding items, wherein T is CH2.337. The compound according to any one of the preceding items, wherein Q isC(CH3)2. P7162PC00 157338. The compound according to any one of the preceding items, wherein T isC(CH3)2.339. The compound according to any one of the preceding items, wherein X is CH2.340. The compound according to any one of the preceding items, wherein Z is CH2.341. The compound according to any one of the preceding items, wherein Z is CF2.342. The compound according to any one of the preceding items, wherein Z is N(H).343. The compound according to any one of the preceding items, wherein Z is N(CH3).344. The compound according to any one of the preceding items, wherein Q is CH2, Tis CH2, and X is absent.345. The compound according to any one of the preceding items, wherein Q is CH2, Tis C(CH3)2, and X is absent.346. The compound according to any one of the preceding items, wherein Q isC(CH3)2, T is CH2, and X is absent.347. The compound according to any one of the preceding items, wherein M is CH2, Qis CH2, T is CH2 or C(CH3)2, and X is absent.348. The compound according to any one of the preceding items, wherein M is O, Q isCH2, T is CH2, and X is absent.349. The compound according to any one of the preceding items, wherein M is S, Q isCH2, T is CH2, and X is absent.350. The compound according to any one of the preceding items, wherein M isN(CH3), Q is CH2, T is CH2, and X is absent.351. The compound according to any one of the preceding items, wherein M is CH2, Qis CH2, T is CH2, and X is absent.352. The compound according to any one of the preceding items, wherein M is CH2, Qis CH2, T is CH2, X is absent, and Z is CH2. P7162PC00 158353. The compound according to any one of the preceding items, wherein M is CH2, Qis CH2, T is CH2, X is absent, and Z is O.354. The compound according to any one of the preceding items, wherein M is CH2, Qis CH2, T is CH2, X is absent, and Z is S.355. The compound according to any one of the preceding items, wherein M is CH2, Qis CH2, T is C(CH3)2, X is absent, and Z is O.356. The compound according to any one of the preceding items, wherein M is CH2, Qis C(CH3)2, T CH2, is X is absent, and Z is O.357. The compound according to any one of the preceding items, wherein M is O, Q isCH2, T is CH2, X is absent, and Z is CH2.358. The compound according to any one of the preceding items, wherein M is O, Q isCH2, T is CH2, X is absent, and Z is O.359. The compound according to any one of the preceding items, wherein M is S, Q isCH2, T is CH2, X is absent, and Z is CH2.360. The compound according to any one of the preceding items, wherein M is S, Q isCH2, T is CH2, X is absent, and Z is O.361. The compound according to any one of the preceding items, wherein M is CH2, Qis CH2, T is CH2, X is absent, and Z is NH.362. The compound according to any one of the preceding items, wherein M is CH2, Qis CH2, T is CH2, X is absent, and Z is NCH3.363. The compound according to any one of the preceding items, wherein M is CH2, Qis CH2, T is CH2, X is absent, and Z is CF2.364. The compound according to any one of the preceding items, wherein M is NCH3,Q is CH2, T is CH2, X is absent, and Z is O.365. The compound according to any one of the preceding items, wherein M is NR11,Qis CH2, T is CH2, X is CH2, and Z is CH2. P7162PC00 159366. The compound according to any one of the preceding items, wherein M is NCH3,Q is CH2, T is CH2, X is CH2, and Z is CH2.367. The compound according to any one of the preceding items, wherein M is NR11,Q is CH2, T is CH2, X is absent, and Z is S.368. The compound according to any one of the preceding items, wherein M is NCH3,Q is CH2, T is CH2, X is absent, and Z is S.369. The compound according to any one of the preceding items, wherein thecompound is not 5-(6-fluoro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4- oxazolidinedione.370. The compound according to any one of the preceding items, wherein thecompound is not 5-(6-chloro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4- oxazolidinedione.371. The compound according to any one of the preceding items, wherein thecompound is selected from the group consisting of: 5-(6-chloro-7-fluoro-8-chromanyl)-1,3-oxazolidine-2,4-dione; 5-(6-chloro-7-fluoro-8-chromanyl)-1,3-thiazolidine-2,4-dione; 5-(3-chloro-2-fluoro-5,6,7,8-tetrahydro-1-naphthyl)-1,3-thiazolidine-2,4-dione; 5-(2-chloro-3-fluoro-5,6,7,8-tetrahydro-1-naphthyl)-1,3-thiazolidine-2,4-dione; 5-(6-chloro-7-fluoro-2,2-dimethyl-8-chromanyl)-1,3-thiazolidine-2,4-dione; 5-(6-chloro-7-methoxy-8-chromanyl)-1,3-thiazolidine-2,4-dione; 5-(4-benzyl-7-chloro-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-1,3- oxazolidine-2,4-dione; 5-(6-chloro-7-fluoro-5-chromanyl)-1,3-thiazolidine-2,4-dione; 5-(6-chloro-7-methoxy-8-chromanyl)-1,3-oxazolidine-2,4-dione; 5-(3-chloro-2-methoxy-5,6,7,8-tetrahydro-1-naphthyl)-1,3-oxazolidine-2,4- dione; 5-(6-chloro-7-fluoro-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4- dione; 5-(7-chloro-6-fluoro-5-chromanyl)-1,3-thiazolidine-2,4-dione; 5-{10-chloro-9-methoxybicyclo[5.4.0]undeca-1(11),7,9-trien-8-yl}-1,3- oxazolidine-2,4-dione; P7162PC00 160 5-(7-chloro-6-methoxy-3,4-dihydro-2H-1-benzothiin-5-yl)-1,3-oxazolidine-2,4- dione; 5-(6-chloro-7-methoxy-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4- dione; 5-(6-chloro-7-ethoxy-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4- dione; 5-(3-chloro-8,8-difluoro-2-methoxy-5,6,7,8-tetrahydro-1-naphthyl)-1,3- oxazolidine-2,4-dione; 5-(3-chloro-2-ethoxy-5,6,7,8-tetrahydro-1-naphthyl)-1,3-oxazolidine-2,4-dione; 5-(3-chloro-5,6,7,8-tetrahydro-1-naphthyl)-1,3-oxazolidine-2,4-dione; 5-(2-chloro-3-fluoro-5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole; 5-(3-chloro-2-fluoro-5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole; 5-(2,3-dichloro-5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole; 5-(7-chloro-6-fluoro-8-chromanyl)-1H-tetraazole; 5-(3-chloro-2-methoxy-5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole; 5-(2,3-difluoro-5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole; 5-(3-fluoro-2-methyl-5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole; 5-(6-chloro-7-methoxy-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-8-yl)-1H- tetraazole; 5-(7-chloro-6-fluoro-3,4-dihydro-2H-1-benzothiin-8-yl)-1H-tetraazole; 5-(7-chloro-6-fluoro-3,4-dihydro-2H-1-benzothiin-5-yl)-1H-tetraazole; 5-(6-chloro-7-fluoro-2,2-dimethyl-8-chromanyl)-1H-tetraazole; 5-(4-benzyl-7-chloro-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole; 5-(6-chloro-7-fluoro-8-chromanyl)-1H-tetraazole; 5-{7-chloro-6-fluoro-4-[(p-fluorophenyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin- 5-yl}-2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(3-thienyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}- 2H-tetraazole; 5-[7-chloro-4-(cyclobutylmethyl)-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl]- 2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(p-methoxyphenyl)methyl]-3,4-dihydro-2H-1,4- benzoxazin-5-yl}-2H-tetraazole; 5-[7-chloro-6-fluoro-4-(2-methoxyethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]- 2H-tetraazole; P7162PC00 161 5-(7-chloro-6-fluoro-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole; 5-(7-chloro-6-fluoro-4-propyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole; 5-{10-chloro-9-methoxybicyclo[5.4.0]undeca-1(7),8,10-trien-8-yl}-2H- tetraazole; 5-{7-chloro-6-fluoro-4-[(o-tolyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}- 2H-tetraazole; 5-(6-chloro-7-methoxy-3,4-dihydro-2H-1-benzothiin-8-yl)-2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(3-furyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}- 2H-tetraazole; 5-(3-chloro-2-ethoxy-5,6,7,8-tetrahydro-1-naphthyl)-2H-tetraazole; 5-(6-chloro-7-fluoro-1,2,3,4-tetrahydro-8-quinolyl)-2H-tetraazole; 5-(6-chloro-7-fluoro-3,4-dihydro-2H-1-benzothiin-8-yl)-2H-tetraazole; 5-(6-chloro-7-fluoro-1-methyl-1,2,3,4-tetrahydro-8-quinolyl)-2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(1,3-oxazol-4-yl)methyl]-3,4-dihydro-2H-1,4- benzoxazin-5-yl}-2H-tetraazole; 5-(7-chloro-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(3-isoxazolyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5- yl}-2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(3-pyridyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}- 2H-tetraazole; 5-(6-chloro-7-methoxy-8-chromanyl)-2H-tetraazole; 5-(4-{(bicyclo[1.1.1]pent-1-yl)methyl}-7-chloro-6-fluoro-3,4-dihydro-2H-1,4- benzoxazin-5-yl)-2H-tetraazole; 5-[7-chloro-4-(cyclopropylmethyl)-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5- yl]-2H-tetraazole; 5-(6-chloro-7-methoxy-1,2,3,4-tetrahydro-8-quinolyl)-2H-tetraazole; 5-(6-chloro-7-methoxy-1-methyl-1,2,3,4-tetrahydro-8-quinolyl)-2H-tetraazole; 5-{7-chloro-4-[2-(cyclopropylmethoxy)ethyl]-6-fluoro-3,4-dihydro-2H-1,4- benzoxazin-5-yl}-2H-tetraazole; 3-(6-chloro-7-fluoro-8-chromanylthio)-1H-1,2,4-triazole; 3-(6-chloro-7-methoxy-8-chromanylthio)-1H-1,2,4-triazole; 4-(6-chloro-7-fluoro-8-chromanyl)-1,2,5-thiadiazol-3-ol; P7162PC00 162 5-{7-chloro-6-fluoro-4-[(5-methyl-3-isoxazolyl)methyl]-3,4-dihydro-2H-1,4- benzoxazin-5-yl}-2H-tetraazole; 5-[7-chloro-6-fluoro-4-(2-fluoroethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-[6-chloro-1-(2-fluoroethyl)-7-methoxy-1,2,3,4-tetrahydro-8-quinolyl]-2H- tetraazole; 5-[7-chloro-6-fluoro-4-(2-isopropoxyethyl)-3,4-dihydro-2H-1,4-benzoxazin-5- yl]-2H-tetraazole; 5-[7-chloro-6-fluoro-4-(2-trifluoromethoxyethyl)-3,4-dihydro-2H-1,4- benzoxazin-5-yl]-2H-tetraazole; 5-(7-chloro-4-propyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-[7-chloro-4-(cyclopropylmethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-[7-chloro-4-(cyclobutylmethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-{7-chloro-4-[(p-fluorophenyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}- 2H-tetraazole; 5-[7-chloro-4-(2,2-difluoroethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-[7-chloro-4-(2-methoxyethyl)-2,2-dimethyl-3,4-dihydro-2H-1,4-benzoxazin-5- yl]-2H-tetraazole; 5-[7-chloro-4-(2,2-difluoroethyl)-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl]- 1H-tetraazole; 5-(7-chloro-6-fluoro-4-isopentyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole; 5-{7-chloro-4-[(2,4-difluorophenyl)methyl]-6-fluoro-3,4-dihydro-2H-1,4- benzoxazin-5-yl}-2H-tetraazole; 5-[7-chloro-4-(2-ethoxyethyl)-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-(7-chloro-6-fluoro-4-isobutyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole; 5-[7-chloro-6-fluoro-4-(4-fluorobutyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-[7-chloro-6-fluoro-4-(4,4,4-trifluorobutyl)-3,4-dihydro-2H-1,4-benzoxazin-5- yl]-2H-tetraazole; P7162PC00 163 5-[7-chloro-4-(2-cyclopropoxyethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-{7-chloro-6-fluoro-4-[(3-fluoro-4-methoxyphenyl)methyl]-3,4-dihydro-2H-1,4- benzoxazin-5-yl}-2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(4-fluoro-2-tolyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin- 5-yl}-2H-tetraazole; 5-(7-chloro-4-{[p-(difluoromethyl)phenyl]methyl}-6-fluoro-3,4-dihydro-2H-1,4- benzoxazin-5-yl)-2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(m-fluorophenyl)methyl]-3,4-dihydro-2H-1,4- benzoxazin-5-yl}-2H-tetraazole; 5-(7-chloro-4-isobutyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-(7-chloro-4-isopropyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-(7-chloro-3,3-dimethyl-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole; 5-(7-chloro-6-fluoro-5-chromanyl)-1H-tetraazole; 5-(6-chloro-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-8-yl)-1H-tetraazole; 5-[4-(cyclopropylmethyl)-7-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-[4-(cyclobutylmethyl)-7-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-(7-fluoro-4-isobutyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-[4-(2,2-difluoroethyl)-7-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-(4-benzyl-7-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-(4-benzyl-7-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-[4-(cyclobutylmethyl)-7-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-(4-isobutyl-7-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-[6-chloro-1-(cyclopropylmethyl)-1,2,3,4-tetrahydro-8-quinolyl]-2H-tetraazole; 5-(6-chloro-1-isobutyl-1,2,3,4-tetrahydro-8-quinolyl)-2H-tetraazole; 5-[4-(cyclopropylmethyl)-7-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-[6-chloro-1-(2,2-difluoroethyl)-1,2,3,4-tetrahydro-8-quinolyl]-2H-tetraazole; 5-(6-chloro-2,3-dihydro-1,4-benzoxathiin-8-yl)-2H-tetraazole; 5-(6-chloro-4-methyl-3,4-dihydro-2H-1,4-benzothiazin-8-yl)-1H-tetraazole; P7162PC00 164 5-(7-chloro-1-methyl-1,2,3,4-tetrahydro-5-quinolyl)-2H-tetraazole; 5-(7-chloro-3,4-dihydro-2H-1-benzothiin-5-yl)-2H-tetraazole; 5-(7-fluoro-3,3-dimethyl-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-1H- tetraazole; 5-(7-fluoro-4-propyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-(6-chloro-7-fluoro-1-methyl-1,2,3,4-tetrahydro-8-quinolyl)-1,3-oxazolidine- 2,4-dione; 5-[7-chloro-4-(cyclopropylmethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-1,3- oxazolidine-2,4-dione; 5-(6-chloro-7-methoxy-1-methyl-1,2,3,4-tetrahydro-8-quinolyl)-1,3-oxazolidine- 2,4-dione; 5-(7-chloro-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-1,3-oxazolidine-2,4- dione; 5-(6-chloro-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4-dione; 5-(7-chloro-6-fluoro-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-1,3- oxazolidine-2,4-dione; 5-(7-chloro-6-fluoro-8-chromanyl)-1,3-oxazolidine-2,4-dione; 5-(6,7-dichloro-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4-dione; 5-(7-chloro-3,3-dimethyl-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-1,3- oxazolidine-2,4-dione; 5-(7-chloro-6-fluoro-5-chromanyl)-1,3-oxazolidine-2,4-dione; 5-(6-bromo-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4-dione; 5-(6-methyl-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4-dione; 5-(7-chloro-5-chromanyl)-1,3-oxazolidine-2,4-dione; 5-(6-fluoro-7-methyl-5-chromanyl)-1,3-oxazolidine-2,4-dione; 5-(6-chloro-4-methyl-3,4-dihydro-2H...

Claims

P7162PC00 353 Claims 1. A compound of Formula (I):Formula (I) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;wherein R5 and R6, or R5 and R9, or R5 and R10, or R5 and R12, or R6 and R9, orR6 and R10, or R6 and R12, or R7 and R8, or R9 and R10, or R9 and R11, orR10 and R11, or R11 and R12, are optionally joined together to form a ringtogether with the intervening atom(s); -R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C2-3alkenyl optionally substituted with one or more, identical or different, substituents R13; -OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -OC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; - SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14and -SC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; and- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14; or R1is linked to R2to form a ring together with the intervening atoms, and R1 is C1-3 alkanediyl optionally substituted with one or more, identical orP7162PC00 354 different, substituents R13, or -O-C1-3 alkanediyl optionally substitutedwith one or more, identical or different, substituents R13, and R2is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:,- R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,or when R5 is linked to R6, R9, R10 or R12 to form a ring, then R5 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R6 is linked to R5, R9, R10 or R12 to form a ring, then R6 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, or when R7 is linked to R8 to form a ring, then R7 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13,P7162PC00 355 or when R8 is linked to R7 to form a ring, then R8 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R9 is linked to R5, R6, R10 or R11 to form a ring, then R9 is C1-3alkanediyl optionally substituted with one or more, identical or different,substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R10is linked to R5, R6, R9or R11, then R10is C1-3alkanediyl optionally substituted with one or more, identical or different, substituents R13;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15,or when R11 is linked to R9, R10, or R12, then R11 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16,or when R12 is linked to R5, R6, or R11, then R12 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium, F, Cl,and CN;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identicalP7162PC00 356 or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17; -R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8bicycloalkyl; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; -R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof; with the proviso that the compound is not selected from the group consisting of 5-(6-fluoro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4-oxazolidinedione and 5-(6-chloro-3,4-dihydro-2H-1-benzopyran-8-yl)-2,4- oxazolidinedione.

2. The compound according to claim 1, wherein compound is of formula (II):P7162PC00 357Formula (II) wherein:- M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; and -SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14;- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14;- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:,- R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;P7162PC00 358- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreP7162PC00 359 F, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8bicycloalkyl; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; -R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.

3. The compound according to any of claims 1 or 2, wherein-R20 is independently selected from the group consisting of H, deuterium andF.

4. The compound according to claim 1, wherein compound is of formula (III):P7162PC00 360Formula (III) wherein:- M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; and -SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14;- R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14;- R3 is selected from the group consisting of H; F and Cl;- R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13;P7162PC00 361- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5 cycloalkyl optionally substituted with one or more, identical ordifferent, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, and 5- to 10-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl,P7162PC00 362 CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; and- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O;or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.

5. The compound according to claim 1, wherein compound is of formula (IV):Formula (IV) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- Z is CR10R9, NR12, O or S;- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; - OC1-3 alkyl optionally substituted with one or more, identical or different, substituents R14; and -SC1-3 alkyl optionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14and C3 cycloalkyl optionally substituted with one or more, identical or different, substituents R14;P7162PC00 363- R3 is selected from the group consisting of H; F and Cl;- R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3alkyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R15;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3 alkyl and -OC3-5 cycloalkyl;- R14 is independently selected from the group consisting of deuterium and F;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identicalP7162PC00 364 or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17; -R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13, C6-10aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different,substituents R19, and 5- to 10-membered heteroaryl optionallysubstituted with one or more, identical or different, substituents R17; -R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F; -R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl; -R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.

6. The compound according to any one of claims 1 to 5, wherein- R1 is selected from the group consisting of H; F; Cl; Br; and -OC1-3 alkyloptionally substituted with one or more, identical or different, substituents R14; -R2 is selected from the group consisting of F; Cl; Br; and C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R14; -R3 is H; and- R14 is independently selected from the group consisting of deuterium and F.P7162PC00 3657. The compound according to any of claims 1 to 6, wherein R1 is selected from thegroup consisting of H; F; Cl and OMe and R2 is selected from the groupconsisting of F and Cl.

8. The compound according to any of claims 1 to 7, wherein M is CH2 or O, and Z isNR12.

9. The compound according to any of claims 1 to 7, wherein M is CH2 and Z isCR10R9, O or S.

10. The compound according to claim 1, wherein the compound is selected from thegroup consisting of: 5-(6-chloro-7-fluoro-8-chromanyl)-1,3-oxazolidine-2,4-dione; 5-(6-chloro-7-fluoro-8-chromanyl)-1,3-thiazolidine-2,4-dione; 5-(3-chloro-2-fluoro-5,6,7,8-tetrahydro-1-naphthyl)-1,3-thiazolidine-2,4-dione; 5-(2-chloro-3-fluoro-5,6,7,8-tetrahydro-1-naphthyl)-1,3-thiazolidine-2,4-dione; 5-(6-chloro-7-fluoro-2,2-dimethyl-8-chromanyl)-1,3-thiazolidine-2,4-dione; 5-(6-chloro-7-methoxy-8-chromanyl)-1,3-thiazolidine-2,4-dione; 5-(4-benzyl-7-chloro-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-1,3- oxazolidine-2,4-dione; 5-(6-chloro-7-fluoro-5-chromanyl)-1,3-thiazolidine-2,4-dione; 5-(6-chloro-7-methoxy-8-chromanyl)-1,3-oxazolidine-2,4-dione; 5-(3-chloro-2-methoxy-5,6,7,8-tetrahydro-1-naphthyl)-1,3-oxazolidine-2,4- dione; 5-(6-chloro-7-fluoro-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4- dione; 5-(7-chloro-6-fluoro-5-chromanyl)-1,3-thiazolidine-2,4-dione; 5-{10-chloro-9-methoxybicyclo[5.4.0]undeca-1(11),7,9-trien-8-yl}-1,3- oxazolidine-2,4-dione; 5-(7-chloro-6-methoxy-3,4-dihydro-2H-1-benzothiin-5-yl)-1,3-oxazolidine-2,4- dione; 5-(6-chloro-7-methoxy-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4- dione; 5-(6-chloro-7-ethoxy-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4- dione;P7162PC00 366 5-(3-chloro-8,8-difluoro-2-methoxy-5,6,7,8-tetrahydro-1-naphthyl)-1,3- oxazolidine-2,4-dione; 5-(3-chloro-2-ethoxy-5,6,7,8-tetrahydro-1-naphthyl)-1,3-oxazolidine-2,4-dione; 5-(3-chloro-5,6,7,8-tetrahydro-1-naphthyl)-1,3-oxazolidine-2,4-dione; 5-(2-chloro-3-fluoro-5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole; 5-(3-chloro-2-fluoro-5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole; 5-(2,3-dichloro-5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole; 5-(7-chloro-6-fluoro-8-chromanyl)-1H-tetraazole; 5-(3-chloro-2-methoxy-5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole; 5-(2,3-difluoro-5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole; 5-(3-fluoro-2-methyl-5,6,7,8-tetrahydro-1-naphthyl)-1H-tetraazole; 5-(6-chloro-7-methoxy-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-8-yl)-1H- tetraazole; 5-(7-chloro-6-fluoro-3,4-dihydro-2H-1-benzothiin-8-yl)-1H-tetraazole; 5-(7-chloro-6-fluoro-3,4-dihydro-2H-1-benzothiin-5-yl)-1H-tetraazole; 5-(6-chloro-7-fluoro-2,2-dimethyl-8-chromanyl)-1H-tetraazole; 5-(4-benzyl-7-chloro-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole; 5-(6-chloro-7-fluoro-8-chromanyl)-1H-tetraazole; 5-{7-chloro-6-fluoro-4-[(p-fluorophenyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin- 5-yl}-2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(3-thienyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}- 2H-tetraazole; 5-[7-chloro-4-(cyclobutylmethyl)-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl]- 2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(p-methoxyphenyl)methyl]-3,4-dihydro-2H-1,4- benzoxazin-5-yl}-2H-tetraazole; 5-[7-chloro-6-fluoro-4-(2-methoxyethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]- 2H-tetraazole; 5-(7-chloro-6-fluoro-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole; 5-(7-chloro-6-fluoro-4-propyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole; 5-{10-chloro-9-methoxybicyclo[5.4.0]undeca-1(7),8,10-trien-8-yl}-2H- tetraazole;P7162PC00 367 5-{7-chloro-6-fluoro-4-[(o-tolyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}- 2H-tetraazole; 5-(6-chloro-7-methoxy-3,4-dihydro-2H-1-benzothiin-8-yl)-2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(3-furyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}- 2H-tetraazole; 5-(3-chloro-2-ethoxy-5,6,7,8-tetrahydro-1-naphthyl)-2H-tetraazole; 5-(6-chloro-7-fluoro-1,2,3,4-tetrahydro-8-quinolyl)-2H-tetraazole; 5-(6-chloro-7-fluoro-3,4-dihydro-2H-1-benzothiin-8-yl)-2H-tetraazole; 5-(6-chloro-7-fluoro-1-methyl-1,2,3,4-tetrahydro-8-quinolyl)-2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(1,3-oxazol-4-yl)methyl]-3,4-dihydro-2H-1,4- benzoxazin-5-yl}-2H-tetraazole; 5-(7-chloro-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(3-isoxazolyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5- yl}-2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(3-pyridyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}- 2H-tetraazole; 5-(6-chloro-7-methoxy-8-chromanyl)-2H-tetraazole; 5-(4-{(bicyclo[1.1.1]pent-1-yl)methyl}-7-chloro-6-fluoro-3,4-dihydro-2H-1,4- benzoxazin-5-yl)-2H-tetraazole; 5-[7-chloro-4-(cyclopropylmethyl)-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5- yl]-2H-tetraazole; 5-(6-chloro-7-methoxy-1,2,3,4-tetrahydro-8-quinolyl)-2H-tetraazole; 5-(6-chloro-7-methoxy-1-methyl-1,2,3,4-tetrahydro-8-quinolyl)-2H-tetraazole; 5-{7-chloro-4-[2-(cyclopropylmethoxy)ethyl]-6-fluoro-3,4-dihydro-2H-1,4- benzoxazin-5-yl}-2H-tetraazole; 3-(6-chloro-7-fluoro-8-chromanylthio)-1H-1,2,4-triazole; 3-(6-chloro-7-methoxy-8-chromanylthio)-1H-1,2,4-triazole; 4-(6-chloro-7-fluoro-8-chromanyl)-1,2,5-thiadiazol-3-ol; 5-{7-chloro-6-fluoro-4-[(5-methyl-3-isoxazolyl)methyl]-3,4-dihydro-2H-1,4- benzoxazin-5-yl}-2H-tetraazole; 5-[7-chloro-6-fluoro-4-(2-fluoroethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-[6-chloro-1-(2-fluoroethyl)-7-methoxy-1,2,3,4-tetrahydro-8-quinolyl]-2H- tetraazole;P7162PC00 368 5-[7-chloro-6-fluoro-4-(2-isopropoxyethyl)-3,4-dihydro-2H-1,4-benzoxazin-5- yl]-2H-tetraazole; 5-[7-chloro-6-fluoro-4-(2-trifluoromethoxyethyl)-3,4-dihydro-2H-1,4- benzoxazin-5-yl]-2H-tetraazole; 5-(7-chloro-4-propyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-[7-chloro-4-(cyclopropylmethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-[7-chloro-4-(cyclobutylmethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-{7-chloro-4-[(p-fluorophenyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin-5-yl}- 2H-tetraazole; 5-[7-chloro-4-(2,2-difluoroethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-[7-chloro-4-(2-methoxyethyl)-2,2-dimethyl-3,4-dihydro-2H-1,4-benzoxazin-5- yl]-2H-tetraazole; 5-[7-chloro-4-(2,2-difluoroethyl)-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl]- 1H-tetraazole; 5-(7-chloro-6-fluoro-4-isopentyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole; 5-{7-chloro-4-[(2,4-difluorophenyl)methyl]-6-fluoro-3,4-dihydro-2H-1,4- benzoxazin-5-yl}-2H-tetraazole; 5-[7-chloro-4-(2-ethoxyethyl)-6-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-(7-chloro-6-fluoro-4-isobutyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole; 5-[7-chloro-6-fluoro-4-(4-fluorobutyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-[7-chloro-6-fluoro-4-(4,4,4-trifluorobutyl)-3,4-dihydro-2H-1,4-benzoxazin-5- yl]-2H-tetraazole; 5-[7-chloro-4-(2-cyclopropoxyethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-{7-chloro-6-fluoro-4-[(3-fluoro-4-methoxyphenyl)methyl]-3,4-dihydro-2H-1,4- benzoxazin-5-yl}-2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(4-fluoro-2-tolyl)methyl]-3,4-dihydro-2H-1,4-benzoxazin- 5-yl}-2H-tetraazole;P7162PC00 369 5-(7-chloro-4-{[p-(difluoromethyl)phenyl]methyl}-6-fluoro-3,4-dihydro-2H-1,4- benzoxazin-5-yl)-2H-tetraazole; 5-{7-chloro-6-fluoro-4-[(m-fluorophenyl)methyl]-3,4-dihydro-2H-1,4- benzoxazin-5-yl}-2H-tetraazole; 5-(7-chloro-4-isobutyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-(7-chloro-4-isopropyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-(7-chloro-3,3-dimethyl-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H- tetraazole; 5-(7-chloro-6-fluoro-5-chromanyl)-1H-tetraazole; 5-(6-chloro-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-8-yl)-1H-tetraazole; 5-[4-(cyclopropylmethyl)-7-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-[4-(cyclobutylmethyl)-7-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-(7-fluoro-4-isobutyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-[4-(2,2-difluoroethyl)-7-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-(4-benzyl-7-fluoro-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-(4-benzyl-7-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-[4-(cyclobutylmethyl)-7-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-(4-isobutyl-7-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole; 5-[6-chloro-1-(cyclopropylmethyl)-1,2,3,4-tetrahydro-8-quinolyl]-2H-tetraazole; 5-(6-chloro-1-isobutyl-1,2,3,4-tetrahydro-8-quinolyl)-2H-tetraazole; 5-[4-(cyclopropylmethyl)-7-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-2H- tetraazole; 5-[6-chloro-1-(2,2-difluoroethyl)-1,2,3,4-tetrahydro-8-quinolyl]-2H-tetraazole; 5-(6-chloro-2,3-dihydro-1,4-benzoxathiin-8-yl)-2H-tetraazole; 5-(6-chloro-4-methyl-3,4-dihydro-2H-1,4-benzothiazin-8-yl)-1H-tetraazole; 5-(7-chloro-1-methyl-1,2,3,4-tetrahydro-5-quinolyl)-2H-tetraazole; 5-(7-chloro-3,4-dihydro-2H-1-benzothiin-5-yl)-2H-tetraazole; 5-(7-fluoro-3,3-dimethyl-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-1H- tetraazole; 5-(7-fluoro-4-propyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-2H-tetraazole;P7162PC00 370 5-(6-chloro-7-fluoro-1-methyl-1,2,3,4-tetrahydro-8-quinolyl)-1,3-oxazolidine- 2,4-dione; 5-[7-chloro-4-(cyclopropylmethyl)-3,4-dihydro-2H-1,4-benzoxazin-5-yl]-1,3- oxazolidine-2,4-dione; 5-(6-chloro-7-methoxy-1-methyl-1,2,3,4-tetrahydro-8-quinolyl)-1,3-oxazolidine- 2,4-dione; 5-(7-chloro-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-1,3-oxazolidine-2,4- dione; 5-(6-chloro-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4-dione; 5-(7-chloro-6-fluoro-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-1,3- oxazolidine-2,4-dione; 5-(7-chloro-6-fluoro-8-chromanyl)-1,3-oxazolidine-2,4-dione; 5-(6,7-dichloro-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4-dione; 5-(7-chloro-3,3-dimethyl-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-5-yl)-1,3- oxazolidine-2,4-dione; 5-(7-chloro-6-fluoro-5-chromanyl)-1,3-oxazolidine-2,4-dione; 5-(6-bromo-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4-dione; 5-(6-methyl-3,4-dihydro-2H-1-benzothiin-8-yl)-1,3-oxazolidine-2,4-dione; 5-(7-chloro-5-chromanyl)-1,3-oxazolidine-2,4-dione; 5-(6-fluoro-7-methyl-5-chromanyl)-1,3-oxazolidine-2,4-dione; 5-(6-chloro-4-methyl-3,4-dihydro-2H-1,4-benzothiazin-8-yl)-1,3-oxazolidine- 2,4-dione; 5-(6-chloro-2,3-dihydro-1,4-benzoxathiin-8-yl)-1,3-oxazolidine-2,4-dione; 5-(7-chloro-6-methoxy-5-chromanyl)-1,3-oxazolidine-2,4-dione; 5-(6,7-difluoro-5-chromanyl)-1,3-oxazolidine-2,4-dione; 5-(7-chloro-6-fluoro-3,4-dihydro-2H-1-benzothiin-5-yl)-1,3-oxazolidine-2,4- dione; and 5-(7-chloro-6-fluoro-2,3-dihydro-1,4-benzodioxin-5-yl)-1,3-oxazolidine-2,4- dione; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.

11. A composition comprising the compound according to any one of claims 1 to 10and a pharmaceutically acceptable carrier.P7162PC00 37112. The compound according to any one of claims 1 to 10 or composition accordingto claim 11 for use as a medicament.

13. The compound according to any one of claims 1 to 10 or composition accordingto claim 11 for use in the treatment of an indication selected from the groupconsisting of myasthenia gravis, autoimmune myasthenia gravis, congenital myasthenia gravis, seronegative myasthenia gravis, muscle specific kinase myasthenia gravis (MuSK-MG), Lambert-Eaton Syndrome, critical illness myopathy, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), critical illness myopathy (CIM), Charcot-Marie Tooth disease, diabetic polyneuropathy, periodic paralysis, hypokalemic periodic paralysis, hyperkalemic periodic paralysis, myotubular myopathy, Duchenne muscular dystrophy, Guillain-Barré syndrome, poliomyelitis, post-polio syndrome, chronic fatigue syndrome, critical illness polyneuropathy, metabolic myopathy, Kennedy´s disorder, sarcopenia and multifocal motor neuropathy.

14. The compound according to any one of claims 1 to 10 or composition accordingto claim 11 for use in reversing and / or ameliorating a neuromuscular blockade.

15. A compound of Formula (I):Formula (I) wherein: -M is CR5R6, NR11, O or S;- Q is CR7R8;- T is CR7R8;- X is absent or CR7R8;- Z is CR10R9, NR12, O or S;wherein R5and R6, or R5and R9, or R5and R10, or R5and R12, or R6and R9, or R6and R10, or R6and R12, or R7and R8, or R9and R10, or R9and R11, orP7162PC00 372 R10and R11, or R11and R12, are optionally joined together to form a ring together with the intervening atom(s);- R1 is selected from the group consisting of H; F; Cl; Br; C1-3 alkyl optionallysubstituted with one or more, identical or different, substituents R13; C2-3alkenyl optionally substituted with one or more, identical or different, substituents R13; -OC1-3alkyl optionally substituted with one or more, identical or different, substituents R14; -OC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; - SC1-3alkyl optionally substituted with one or more, identical or different, substituents R14and -SC3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R14; and R2is selected from the group consisting of F; Cl; Br; C1-3alkyl optionally substituted with one or more, identical or different, substituents R14and C3cycloalkyl optionally substituted with one or more, identical or different, substituents R14; or R1is linked to R2to form a ring together with the intervening atoms, and R1is C1-3 alkanediyl optionally substituted with one or more, identical or different, substituents R13, or -O-C1-3 alkanediyl optionally substituted with one or more, identical or different, substituents R13, and R2is C1-3 alkanediyl optionally substituted with one or more, identical or different, substituents R13;- R3 is selected from the group consisting of H; F and Cl;- R4 is selected from the group consisting of:,- R5 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3alkyl substituted with R15,P7162PC00 373 or when R5is linked to R6, R9, R10or R12to form a ring, then R5is C1-3alkanediyl optionally substituted with one or more, identical or different, substituents R13;- R6 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R6is linked to R5, R9, R10or R12to form a ring, then R6is C1-3alkanediyl optionally substituted with one or more, identical or different, substituents R13;- R7 is independently selected from the group consisting of H, deuterium, Fand C1-3alkyl optionally substituted with one or more, identical or different, substituents R13, or when R7is linked to R8to form a ring, then R7is C1-3alkanediyl optionally substituted with one or more, identical or different, substituents R13;- R8 is independently selected from the group consisting of H, deuterium, F,and C1-3 alkyl optionally substituted with one or more, identical or different, substituents R13, or when R8is linked to R7to form a ring, then R8is C1-3 alkanediyl optionally substituted with one or more, identical or different, substituents R13;- R9 is selected from the group consisting of H, deuterium, F, and C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13, or when R9is linked to R5, R6, R10or R11to form a ring, then R9is C1-3 alkanediyl optionally substituted with one or more, identical or different, substituents R13;- R10 is selected from the group consisting of H; deuterium; F; C1-3 alkyloptionally substituted with one or more, identical or different, substituents R13; C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3 alkyl substituted with R16, or when R10is linked to R5, R6, R9or R11, then R10is C1-3 alkanediyl optionally substituted with one or more, identical or different, substituents R13;- R11 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5 cycloalkylP7162PC00 374 optionally substituted with one or more, identical or different, substituents R13; and C1-3alkyl substituted with R15, or when R11is linked to R9, R10, or R12, then R11is C1-3alkanediyl optionally substituted with one or more, identical or different, substituents R13;- R12 is selected from the group consisting of H; C1-3 alkyl optionally substitutedwith one or more, identical or different, substituents R13; C3-5cycloalkyl optionally substituted with one or more, identical or different, substituents R13; and C1-3alkyl substituted with R16, or when R12 is linked to R5, R6, or R11, then R12 is C1-3 alkanediyl optionallysubstituted with one or more, identical or different, substituents R13;- R13 is independently selected from the group consisting of deuterium, F, Cl,CN, -OC1-3alkyl and -OC3-5cycloalkyl;- R14 is independently selected from the group consisting of deuterium, F, Cl,and CN;- R15 is independently selected from the group consisting of C3-5 cycloalkyloptionally substituted with one or more, identical or different, substituents R13, phenyl optionally substituted with one or more, identical or different, substituents R17and 5-membered heteroaryl optionally substituted with one or more, identical or different, substituents R17;- R16 is independently selected from the group consisting of -C(=O)N(R18)2, -NR18-C(=O)-R18, -NR18-SO2-R18, -SO2-N(R18)2, -SO2-R18, -C(=O)-R18, - OR18, -SR18, -OCH2R18, C1-3 alkyl optionally substituted with one or moreF, -C3-5 cycloalkyl optionally substituted with one or more, identical ordifferent, substituents R13, C6-10 aryl optionally substituted with one or more, identical or different, substituents R17, 5- to 10-memberedheterocycle optionally substituted with one or more, identical or different, substituents R19, 5- to 10-membered heteroaryl optionally substitutedwith one or more, identical or different, substituents R17, and C5-8 bicycloalkyl;- R17 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, and F;P7162PC00 375- R18 is independently selected from the group consisting of deuterium, F, Cl,CN, C1-3 alkyl optionally substituted with one or more F, and C3-5cycloalkyl;- R19 is independently selected from the group consisting of deuterium,methoxy, -OCF3, OCF2Cl, OCF2H, OCFH2, OCD3, Me, CF3, CF2Cl, CF2H, CFH2, CD3, cyclopropyl, NH2, -NHAc, -C(=O)-NH2, nitro, cyano, Cl, Br, F and =O; and- R20 is independently selected from the group consisting of H, deuterium andF; or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof; for use in treating, ameliorating and / or preventing a neuromuscular disorder, and / or for use in reversing and / or ameliorating a neuromuscular blockade.

Images